<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1397" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1397/" /><meta name="ncbi_pagename" content="Xeroderma Pigmentosum - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Xeroderma Pigmentosum - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Xeroderma Pigmentosum" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2016/09/29" /><meta name="citation_author" content="Kenneth H Kraemer" /><meta name="citation_author" content="John J DiGiovanna" /><meta name="citation_pmid" content="20301571" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1397/" /><meta name="citation_keywords" content="DeSanctis-Cacchione Syndrome" /><meta name="citation_keywords" content="XPA-Related Xeroderma Pigmentosum" /><meta name="citation_keywords" content="ERCC3-Related Xeroderma Pigmentosum" /><meta name="citation_keywords" content="XPC-Related Xeroderma Pigmentosum" /><meta name="citation_keywords" content="ERCC2-Related Xeroderma Pigmentosum" /><meta name="citation_keywords" content="DDB2-Related Xeroderma Pigmentosum" /><meta name="citation_keywords" content="ERCC4-Related Xeroderma Pigmentosum" /><meta name="citation_keywords" content="ERCC5-Related Xeroderma Pigmentosum" /><meta name="citation_keywords" content="POLH-Related Xeroderma Pigmentosum" /><meta name="citation_keywords" content="ERCC1-Related Xeroderma Pigmentosum" /><meta name="citation_keywords" content="DNA damage-binding protein 2" /><meta name="citation_keywords" content="DNA excision repair protein ERCC-1" /><meta name="citation_keywords" content="DNA polymerase eta" /><meta name="citation_keywords" content="DNA repair endonuclease XPF" /><meta name="citation_keywords" content="DNA repair protein complementing XP-A cells" /><meta name="citation_keywords" content="DNA repair protein complementing XP-C cells" /><meta name="citation_keywords" content="DNA repair protein complementing XP-G cells" /><meta name="citation_keywords" content="General transcription and DNA repair factor IIH helicase subunit XPB" /><meta name="citation_keywords" content="General transcription and DNA repair factor IIH helicase subunit XPD" /><meta name="citation_keywords" content="DDB2" /><meta name="citation_keywords" content="ERCC1" /><meta name="citation_keywords" content="ERCC2" /><meta name="citation_keywords" content="ERCC3" /><meta name="citation_keywords" content="ERCC4" /><meta name="citation_keywords" content="ERCC5" /><meta name="citation_keywords" content="POLH" /><meta name="citation_keywords" content="XPA" /><meta name="citation_keywords" content="XPC" /><meta name="citation_keywords" content="Xeroderma Pigmentosum" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Xeroderma Pigmentosum" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Kenneth H Kraemer" /><meta name="DC.Contributor" content="John J DiGiovanna" /><meta name="DC.Date" content="2016/09/29" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1397/" /><meta name="description" content="Xeroderma pigmentosum (XP) is characterized by:" /><meta name="og:title" content="Xeroderma Pigmentosum" /><meta name="og:type" content="book" /><meta name="og:description" content="Xeroderma pigmentosum (XP) is characterized by:" /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1397/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/xp/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1397/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8D7293E0404AD100000000058701DC.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1397_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1397_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/sedt/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/xq28-dup/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1397_"><span class="title" itemprop="name">Xeroderma Pigmentosum</span></h1><p class="contrib-group"><span itemprop="author">Kenneth H Kraemer</span>, MD and <span itemprop="author">John J DiGiovanna</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK1397_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1397_ai__"><div class="contrib half_rhythm"><span itemprop="author">Kenneth H Kraemer</span>, MD<div class="affiliation small">Dermatology Branch<br />Center for Cancer Research<br />National Cancer Institute<br />Bethesda, Maryland<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.hin@kremeark" class="oemail">vog.hin@kremeark</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">John J DiGiovanna</span>, MD<div class="affiliation small">Dermatology Branch<br />Center for Cancer Research<br />National Cancer Institute<br />Bethesda, Maryland<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.hin.liam@avoigidj" class="oemail">vog.hin.liam@avoigidj</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">June 20, 2003</span>; Last Update: <span itemprop="dateModified">September 29, 2016</span>.</p><p><em>Estimated reading time: 41 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="xp.Summary" itemprop="description"><h2 id="_xp_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Xeroderma pigmentosum (XP) is characterized by:</p><ul><li class="half_rhythm"><div>Sun sensitivity (severe sunburn with blistering, persistent erythema on minimal sun exposure in ~60% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals), with marked freckle-like pigmentation of the face before age two years in most affected individuals;</div></li><li class="half_rhythm"><div>Sunlight-induced ocular involvement (photophobia, keratitis, atrophy of the skin of the lids);</div></li><li class="half_rhythm"><div>Greatly increased risk of sunlight-induced cutaneous neoplasms (basal cell carcinoma, squamous cell carcinoma, melanoma).</div></li></ul><p>Approximately 25% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have neurologic manifestations (acquired microcephaly, diminished or absent deep tendon stretch reflexes, progressive sensorineural hearing loss, and progressive cognitive impairment). The most common causes of death are skin cancer, neurologic degeneration, and internal cancer. The median age at death in persons with XP with neurodegeneration (29 years) was found to be younger than that in persons with XP without neurodegeneration (37 years).</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of XP is made on the basis of clinical findings and family history and/or by the identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>DDB2</i>, <i>ERCC1</i>, <i>ERCC2</i>, <i>ERCC3</i>, <i>ERCC4</i>, <i>ERCC5</i>, <i>POLH</i>, <i>XPA</i>, or <i>XPC</i>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Small, premalignant skin lesions such as actinic keratoses can be treated by freezing with liquid nitrogen; larger areas can be treated with field treatments such as topical 5-fluorouracil or imiquimod. Rarely, therapeutic dermatome shaving or dermabrasion has been used; skin neoplasms can be treated (as in persons without XP) with electrodesiccation and curettage, or surgical excision; skin cancers that are recurrent or in locations at high risk for recurrence are best treated with Mohs micrographic surgery. Oral isotretinoin or acitretin can prevent new skin neoplasms but have many side effects. Neoplasms of the eyelids, conjunctiva, and cornea can be treated surgically; corneal transplantation may improve the visual impairment resulting from severe keratitis. Hearing loss may be treated with hearing aids.</p><p><i>Prevention of primary manifestations:</i> Avoid sun and other UV exposure to the skin and eyes; measurement of UV light with a light meter in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual's home, school, and/or work environment so that high levels of environmental UV can be identified and eliminated.</p><p><i>Prevention of secondary complications:</i> Dietary supplementation with oral vitamin D as needed.</p><p><i>Surveillance:</i> Skin examinations by a physician every three to 12 months; periodic routine eye and neurologic examinations and audiograms.</p><p><i>Agents/circumstances to avoid:</i> UV exposure from sunlight and artificial sources of UV radiation, cigarette smoke.</p><p><i>Evaluation of relatives at risk:</i> If family-specific pathogenic variants have been identified, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of at-risk sibs can permit early diagnosis and rigorous sun protection from an early age.</p><p><i>Pregnancy management</i>: Systemic retinoids (isotretinoin, acitretin) may be used as skin cancer chemopreventive agents. These drugs are known to be teratogenic to a developing fetus and pose a high risk for birth defects. Women of reproductive age who are taking a systemic retinoid must use effective contraception and be monitored with regular pregnancy tests.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>XP is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Once the pathogenic variants have been identified in an affected family member, <a class="def" href="/books/n/gene/glossary/def-item/carrier-testing/">carrier testing</a> for at-risk family members and prenatal testing for pregnancies at increased risk are possible.</p></div></div><div id="xp.Diagnosis"><h2 id="_xp_Diagnosis_">Diagnosis</h2><div id="xp.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Xeroderma pigmentosum (XP) <b>should be suspected</b> in individuals with the following skin, eye, nervous system, and family history findings.</p><p><b>Skin</b></p><ul><li class="half_rhythm"><div>Acute sun sensitivity (severe sunburn with blistering or persistent erythema on minimal sun exposure)</div></li><li class="half_rhythm"><div>Marked freckle-like pigmentation (lentigos) on the face before age two years</div></li><li class="half_rhythm"><div>Skin cancer within the first decade of life</div></li></ul><p><b>Eye</b></p><ul><li class="half_rhythm"><div>Photophobia with prominent conjunctival injection</div></li><li class="half_rhythm"><div>Severe keratitis, sometimes resulting in corneal opacification and vascularization</div></li><li class="half_rhythm"><div>Increased pigmentation of the lids with loss of lashes</div></li><li class="half_rhythm"><div>Atrophy of the skin of the lids resulting in ectropion, entropion, or in severe cases, complete loss of the lids</div></li></ul><p><b>Nervous system</b></p><ul><li class="half_rhythm"><div>Diminished or absent deep tendon stretch reflexes. EMG and nerve conduction velocities may show an axonal (or mixed) neuropathy.</div></li><li class="half_rhythm"><div>Progressive sensorineural hearing loss. Audiometry may reveal early high-tone hearing loss.</div></li><li class="half_rhythm"><div>Acquired microcephaly. CT and MRI of the brain may show enlarged ventricles with thinning of the cortex and thickening of the bones of the skull.</div></li><li class="half_rhythm"><div>Progressive cognitive impairment</div></li></ul><p><b>Family history</b></p><ul><li class="half_rhythm"><div>Consistent with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> inheritance</div><div>Note: Absence of a family history of XP does not preclude the diagnosis.</div></li></ul></div><div id="xp.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of XP <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> on the basis of clinical findings and family history (see <a href="#xp.Suggestive_Findings">Suggestive Findings</a>) and/or by the identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in one of the genes listed in <a class="figpopup" href="/books/NBK1397/table/xp.T.molecular_genetic_testing_used_in_x/?report=objectonly" target="object" rid-figpopup="figxpTmoleculargenetictestingusedinx" rid-ob="figobxpTmoleculargenetictestingusedinx">Table 1</a>.</p><p>Molecular testing approaches can include <b>serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>, and <b>more comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>.</p><p><b>Serial single <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing<i>.</i></b> The choice of which genes to analyze can be guided by the clinical features and the relative frequency in the population where the individual was born (see <a class="figpopup" href="/books/NBK1397/table/xp.T.molecular_genetic_testing_used_in_x/?report=objectonly" target="object" rid-figpopup="figxpTmoleculargenetictestingusedinx" rid-ob="figobxpTmoleculargenetictestingusedinx">Table 1</a>, <a class="figpopup" href="/books/NBK1397/table/xp.T.phenotype_correlations_by_gene_in_x/?report=objectonly" target="object" rid-figpopup="figxpTphenotypecorrelationsbygeneinx" rid-ob="figobxpTphenotypecorrelationsbygeneinx">Table 2</a>, <a class="figpopup" href="/books/NBK1397/figure/xp.F1/?report=objectonly" target="object" rid-figpopup="figxpF1" rid-ob="figobxpF1">Figure 1</a>, and <a class="bk_pop" href="#xp.REF.digiovanna.2012.785">DiGiovanna &#x00026; Kraemer [2012]</a>).</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figxpF1" co-legend-rid="figlgndxpF1"><a href="/books/NBK1397/figure/xp.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="figxpF1" rid-ob="figobxpF1"><img class="small-thumb" src="/books/NBK1397/bin/xp-Image001.gif" src-large="/books/NBK1397/bin/xp-Image001.jpg" alt="Figure 1. " /></a><div class="icnblk_cntnt" id="figlgndxpF1"><h4 id="xp.F1"><a href="/books/NBK1397/figure/xp.F1/?report=objectonly" target="object" rid-ob="figobxpF1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">Relationship between genotype and phenotype in the xeroderma pigmentosum-Cockayne syndrome-trichothiodystrophy spectrum Italicized letters in ovals indicate mutated genes. Rectangles are phenotypes. Because of the complexity of the relationship, it is <a href="/books/NBK1397/figure/xp.F1/?report=objectonly" target="object" rid-ob="figobxpF1">(more...)</a></p></div></div><p>Testing first for founder variants present in specific parts of the world may be considered:</p><ul><li class="half_rhythm"><div><b><i>XPA</i></b></div><ul><li class="half_rhythm"><div>India: c.335_338delTTATinsCATAAGAAA [<a class="bk_pop" href="#xp.REF.tamhankar.2015.16">Tamhankar et al 2015</a>]</div></li><li class="half_rhythm"><div>Japan: c.390-1G&#x0003e;C (<a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> frequency of 1%) [<a class="bk_pop" href="#xp.REF.hirai.2006.171">Hirai et al 2006</a>]</div></li><li class="half_rhythm"><div>Tunisia: p.Arg228Ter [<a class="bk_pop" href="#xp.REF.messaoud.2010.883">Messaoud et al 2010</a>]</div></li></ul></li><li class="half_rhythm"><div><b><i>XPC</i>.</b> North Africa: c.1643_1644delTG [<a class="bk_pop" href="#xp.REF.soufir.2010.1537">Soufir et al 2010</a>, <a class="bk_pop" href="#xp.REF.hadjrabia.2013.1109">Hadj-Rabia et al 2013</a>, <a class="bk_pop" href="#xp.REF.jerbi.2016.439">Jerbi et al 2016</a>]</div></li><li class="half_rhythm"><div><b><i>ERCC2</i>.</b> Iraqi Jewish: p.Arg683Gln [<a class="bk_pop" href="#xp.REF.falikzaccai.2012.505">Falik-Zaccai et al 2012</a>]</div></li><li class="half_rhythm"><div><b><i>POLH</i></b></div><ul><li class="half_rhythm"><div>Tunisia / North Africa: Del <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 10 [<a class="bk_pop" href="#xp.REF.ben_rekaya.2014">Ben Rekaya et al 2014</a>]</div></li><li class="half_rhythm"><div>Japan: c.490G&#x0003e;T (<a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variant); p.Ser242Ter; p.Glu306Ter and c.1661delA [<a class="bk_pop" href="#xp.REF.masaki.2008.144">Masaki et al 2008</a>]</div></li><li class="half_rhythm"><div>Basque / Northern Spain: c.764+1G&#x0003e;A [<a class="bk_pop" href="#xp.REF.calmels.2016.26">Calmels et al 2016</a>]</div></li></ul></li></ul><p><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>DDB2</i>, <i>ERCC1</i>, <i>ERCC2</i>, <i>ERCC3</i>, <i>ERCC4</i>, <i>ERCC5</i>, <i>POLH,</i>
<i>XPA</i>, and <i>XPC</i> and other genes of interest (see <a href="#xp.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included and the <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of multigene panels vary by laboratory and over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p><p><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> and <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> may be considered if serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing (and/or use of a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> that includes <i>DDB2</i>, <i>ERCC1</i>, <i>ERCC2</i>, <i>ERCC3</i>, <i>ERCC4</i>, <i>ERCC5</i>, <i>POLH,</i>
<i>XPA</i>, and <i>XPC</i>) fails to confirm a diagnosis in an individual with features of XP. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different gene or genes that results in a similar clinical presentation). For an introduction to comprehensive genomic testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><div id="xp.T.molecular_genetic_testing_used_in_x" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Xeroderma Pigmentosum</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1397/table/xp.T.molecular_genetic_testing_used_in_x/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__xp.T.molecular_genetic_testing_used_in_x_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_2" colspan="3" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Proportion of XP Attributed to Pathogenic Variants in This Gene&#x000a0;<sup>2</sup></th><th id="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants&#x000a0;<sup>3</sup> Detectable by Test Method</th></tr><tr><th headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_2" id="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">US</th><th headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_2" id="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Japan</th><th headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_2" id="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Europe</th><th headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_3" id="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>4</sup></th><th headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_3" id="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></th></tr></thead><tbody><tr><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>DDB2</i></td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_2 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3%</td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_2 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3%</td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_2 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_3 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">15/15 alleles&#x000a0;<sup>6</sup></td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_3 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>7</sup></td></tr><tr><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ERCC1</i></td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_2 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_1 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_2 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_3" colspan="3" rowspan="1" style="text-align:left;vertical-align:middle;">Rare</td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_3 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4/4 alleles&#x000a0;<sup>8</sup></td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_3 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td></tr><tr><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ERCC2</i></td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_2 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">28%</td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_2 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5%</td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_2 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">16%</td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_3 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;99%</td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_3 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td></tr><tr><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ERCC3</i></td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_2 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1%</td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_2 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0%</td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_2 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2%</td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_3 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8/8 alleles&#x000a0;<sup>9</sup></td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_3 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td></tr><tr><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ERCC4</i>&#x000a0;<sup>10</sup></td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_2 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0%</td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_2 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">7%</td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_2 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3%</td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_3 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~99%</td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_3 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Rare&#x000a0;<sup>11</sup></td></tr><tr><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ERCC5</i></td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_2 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3%</td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_2 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1%</td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_2 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">9%</td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_3 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;99%</td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_3 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td></tr><tr><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>POLH</i></td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_2 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">7%</td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_2 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">25%</td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_2 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">13%</td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_3 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">25/40 alleles; 33/42 alleles&#x000a0;<sup>12</sup></td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_3 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">15/40 alleles; 9/42 alleles&#x000a0;<sup>12</sup></td></tr><tr><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>XPA</i></td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_2 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">9%</td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_2 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">55%&#x000a0;<sup>13</sup></td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_2 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">20%</td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_3 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_3 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td></tr><tr><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>XPC</i></td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_2 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">43%</td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_2 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3%</td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_2 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">31%</td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_3 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">7/12 alleles&#x000a0;<sup>14</sup></td><td headers="hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_1_3 hd_h_xp.T.molecular_genetic_testing_used_in_x_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5/12 alleles&#x000a0;<sup>14</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="xp.TF.1.1"><p class="no_margin">See <a href="/books/NBK1397/#xp.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="xp.TF.1.2"><p class="no_margin">Frequencies are taken from <a class="bk_pop" href="#xp.REF.bradford.2011.168">Bradford et al [2011]</a> for 106 individuals with XP in the US, <a class="bk_pop" href="#xp.REF.moriwaki.2001.47">Moriwaki &#x00026; Kraemer [2001]</a> for 291 individuals with XP in Japan, and <a class="bk_pop" href="#xp.REF.fassihi.2016.e1236">Fassihi et al [2016]</a> for 89 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals seen at a clinic in London, UK.</p></div></dd><dt>3. </dt><dd><div id="xp.TF.1.3"><p class="no_margin">See <a href="#xp.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>4. </dt><dd><div id="xp.TF.1.4"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>5. </dt><dd><div id="xp.TF.1.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods that may be used include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="xp.TF.1.6"><p class="no_margin"><a class="bk_pop" href="#xp.REF.nichols.1996.24317">Nichols et al [1996]</a>, <a class="bk_pop" href="#xp.REF.rapi_otrin.2003.1507">Rapi&#x00107;-Otrin et al [2003]</a>, <a class="bk_pop" href="#xp.REF.fassihi.2016.e1236">Fassihi et al [2016]</a></p></div></dd><dt>7. </dt><dd><div id="xp.TF.1.7"><p class="no_margin">No data on detection rate of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> are available.</p></div></dd><dt>8. </dt><dd><div id="xp.TF.1.8"><p class="no_margin"><a class="bk_pop" href="#xp.REF.jaspers.2007.457">Jaspers et al [2007]</a>, <a class="bk_pop" href="#xp.REF.kashiyama.2013.807">Kashiyama et al [2013]</a></p></div></dd><dt>9. </dt><dd><div id="xp.TF.1.9"><p class="no_margin"><a class="bk_pop" href="#xp.REF.oh.2006.1092">Oh et al [2006]</a>, <a class="bk_pop" href="#xp.REF.fassihi.2016.e1236">Fassihi et al [2016]</a></p></div></dd><dt>10. </dt><dd><div id="xp.TF.1.10"><p class="no_margin">Individuals with pathogenic variants in <i>ERCC4</i> have been reported with phenotypes of Fanconi anemia, XP/Cockayne Syndrome complex or with combined XP/CS/FA [<a class="bk_pop" href="#xp.REF.bogliolo.2013.800">Bogliolo et al 2013</a>, <a class="bk_pop" href="#xp.REF.kashiyama.2013.807">Kashiyama et al 2013</a>].</p></div></dd><dt>11. </dt><dd><div id="xp.TF.1.11"><p class="no_margin">A <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 3 has been reported [<a class="bk_pop" href="#xp.REF.ahmad.2010.e1000871">Ahmad et al 2010</a>].</p></div></dd><dt>12. </dt><dd><div id="xp.TF.1.12"><p class="no_margin">The majority of reported <i>POLH</i> variants are detectable by sequencing; however, single- and multiexon deletions have been reported. The frequency of deletions varies by population [<a class="bk_pop" href="#xp.REF.broughton.2002.815">Broughton et al 2002</a>, <a class="bk_pop" href="#xp.REF.opletalova.2014.117">Opletalova et al 2014</a>]. Deletion of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 10 accounted for 32/32 alleles in Tunisian patients with XP-V [<a class="bk_pop" href="#xp.REF.ben_rekaya.2014">Ben Rekaya et al 2014</a>].</p></div></dd><dt>13. </dt><dd><div id="xp.TF.1.13"><p class="no_margin">Common in Japan, rare in the US and Europe</p></div></dd><dt>14. </dt><dd><div id="xp.TF.1.14"><p class="no_margin"><a class="bk_pop" href="#xp.REF.chavanne.2000.1974">Chavanne et al [2000]</a></p></div></dd></dl></div></div></div><p><b>Functional tests</b> on living cells including cellular ultraviolet (UV) hypersensitivity, unscheduled DNA synthesis (UDS), and host-cell reactivation can be used to screen for abnormalities in DNA repair, but are not commonly available [<a class="bk_pop" href="#xp.REF.stefanini.2008">Stefanini &#x00026; Kraemer 2008</a>, <a class="bk_pop" href="#xp.REF.kraemer.2012">Kraemer &#x00026; Ruenger 2012</a>, <a class="bk_pop" href="#xp.REF.ruenger.2012">Ruenger et al 2012</a>].</p><p>Click <a href="/books/NBK1397/bin/xp-Functional_tests.pdf">here</a> (pdf) for additional test options available on a research basis only.</p></div></div><div id="xp.Clinical_Characteristics"><h2 id="_xp_Clinical_Characteristics_">Clinical Characteristics</h2><div id="xp.Clinical_Description"><h3>Clinical Description</h3><p>The findings in 106 individuals with XP examined at the NIH in a long-term study from 1971 to 2009 by <a class="bk_pop" href="#xp.REF.bradford.2011.168">Bradford et al [2011]</a> are summarized below. Citations from earlier studies are provided as well.</p><p><b>Xeroderma pigmentosum (XP)</b></p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Cutaneous.</b> Approximately 60% of individuals with XP have a history of acute sunburn reaction on minimal UV exposure. The other 40% of individuals with XP tan without excessive burning [<a class="bk_pop" href="#xp.REF.sethi.2013.1279">Sethi et al 2013</a>]. In all individuals, numerous freckle-like hyperpigmented macules appear on sun-exposed skin. The median onset of the cutaneous symptoms is between ages one and two years [<a class="bk_pop" href="#xp.REF.kraemer.1987.241">Kraemer et al 1987</a>, <a class="bk_pop" href="#xp.REF.kraemer.1994.1018">Kraemer et al 1994</a>]. These abnormalities are limited to sun-exposed areas.</div><div class="half_rhythm">Continued sun exposure causes the skin to become dry and parchment-like with increased pigmentation; hence the name xeroderma pigmentosum ("dry pigmented skin"). Most individuals with XP develop xerosis (dry skin) and poikiloderma (the constellation of hyper- and hypopigmentation, atrophy, and telangiectasia). Premalignant actinic keratoses develop at an early age. XP is an example of accelerated photo-aging. The appearance of sun-exposed skin in children with XP is similar to that occurring in farmers and sailors after many years of extreme sun exposure.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Ocular.</b> Ocular abnormalities are almost as common as the cutaneous abnormalities [<a class="bk_pop" href="#xp.REF.kraemer.1987.241">Kraemer et al 1987</a>, <a class="bk_pop" href="#xp.REF.kraemer.1994.1018">Kraemer et al 1994</a>]. Findings may begin in the first decade of life and are usually limited to the anterior, UV-exposed portions of the eyes: conjunctiva, cornea, and lids [<a class="bk_pop" href="#xp.REF.dollfus.2003.107">Dollfus et al 2003</a>, <a class="bk_pop" href="#xp.REF.brooks.2013.1324">Brooks et al 2013</a>]. The benign conjunctival inflammatory masses that develop can spread to obscure the cornea. Epithelioma, squamous cell carcinoma, and melanoma of UV-exposed portions of the eye are common. The ocular manifestations may be more severe in black individuals [<a class="bk_pop" href="#xp.REF.dollfus.2003.107">Dollfus et al 2003</a>, <a class="bk_pop" href="#xp.REF.ramkumar.2011.348">Ramkumar et al 2011</a>, <a class="bk_pop" href="#xp.REF.brooks.2013.1324">Brooks et al 2013</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Neurologic.</b> Progressive neurologic abnormalities that worsen slowly were reported in approximately 25% of 106 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals [<a class="bk_pop" href="#xp.REF.rapin.2000.1442">Rapin et al 2000</a>, <a class="bk_pop" href="#xp.REF.kraemer.2007.1388">Kraemer et al 2007</a>, <a class="bk_pop" href="#xp.REF.digiovanna.2012.785">DiGiovanna &#x00026; Kraemer 2012</a>, <a class="bk_pop" href="#xp.REF.lai.2013.4">Lai et al 2013</a>, <a class="bk_pop" href="#xp.REF.totonchy.2013.194">Totonchy et al 2013</a>, <a class="bk_pop" href="#xp.REF.viana.2013.1230">Viana et al 2013</a>]. The onset may be early in infancy or, in some individuals, delayed until the second decade or later [<a class="bk_pop" href="#xp.REF.rapin.2000.1442">Rapin et al 2000</a>]. The neurologic abnormalities may be mild (e.g., <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> hyporeflexia) or severe, with microcephaly, progressive intellectual impairment, sensorineural hearing loss beginning with high frequencies, spasticity, ataxia, and/or seizures. During an upper respiratory infection some individuals may develop difficulty swallowing or, rarely, vocal cord paralysis [<a class="bk_pop" href="#xp.REF.ohto.2004.222">Ohto et al 2004</a>].</div><div class="half_rhythm">The predominant neuropathologic abnormality found at autopsy in individuals with neurologic symptoms is loss (or absence) of neurons, particularly in the cerebrum and cerebellum. There is evidence for a primary axonal degeneration in peripheral nerves, in some cases with secondary demyelination [<a class="bk_pop" href="#xp.REF.rapin.2000.1442">Rapin et al 2000</a>, <a class="bk_pop" href="#xp.REF.lai.2013.4">Lai et al 2013</a>, <a class="bk_pop" href="#xp.REF.viana.2013.1230">Viana et al 2013</a>].</div><div class="half_rhythm">Reduced nerve conduction velocity may also be present on nerve conduction studies.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Cutaneous neoplasia.</b> If aggressive UV avoidance is not begun early, accumulated sunlight-induced DNA damage is likely to result in skin cancer within the first decade of life. <a class="bk_pop" href="#xp.REF.bradford.2011.168">Bradford et al [2011]</a> found that individuals with XP younger than age 20 years were at increased risk for the following cancers:</div><ul><li class="half_rhythm"><div><b>Non-melanoma (basal cell and squamous cell) skin cancer</b> at UV-exposed sites. The &#x0003e;10,000-fold increased risk was associated with a median age of onset of nine years, nearly 60 years earlier than in the US general population.</div></li><li class="half_rhythm"><div><b>Cutaneous melanoma.</b> The &#x0003e;2000-fold increased risk was associated with the median age of onset of 22 years, more than 30 years earlier than in the US general population.</div></li><li class="half_rhythm"><div>Surprisingly, the persons with XP with the most severe sun sensitivity had a later onset of skin cancer &#x02013; probably because they used greater sun protection.</div></li></ul></li></ul><p><b>Other neoplasias.</b> Review of the world literature has revealed a substantial number of people with XP who have oral cavity neoplasms, particularly squamous cell carcinoma of the tip of the tongue, a presumed sun-exposed location [<a class="bk_pop" href="#xp.REF.kraemer.1987.241">Kraemer et al 1987</a>, <a class="bk_pop" href="#xp.REF.kraemer.1994.1018">Kraemer et al 1994</a>, <a class="bk_pop" href="#xp.REF.butt.2010.534">Butt et al 2010</a>].</p><p>Gliomas of the brain and spinal cord, tumors of the lung, uterus, breast, pancreas, stomach, kidney, and testicles, and leukemia have been reported in a few individuals with XP [<a class="bk_pop" href="#xp.REF.digiovanna.1998.153">DiGiovanna et al 1998</a>, <a class="bk_pop" href="#xp.REF.bradford.2011.168">Bradford et al 2011</a>, <a class="bk_pop" href="#xp.REF.lai.2013.4">Lai et al 2013</a>, <a class="bk_pop" href="#xp.REF.fassihi.2016.e1236">Fassihi et al 2016</a>].</p><p>Because some of the carcinogens in cigarette smoke bind to DNA resulting in damage that is repaired by the nucleotide excision repair (NER) system, this unrepaired DNA damage may contribute to the development of lung cancer in individuals with XP. Overall, these reports suggest an approximate ten- to 20-fold increase in internal neoplasms in XP [<a class="bk_pop" href="#xp.REF.kraemer.1987.241">Kraemer et al 1987</a>, <a class="bk_pop" href="#xp.REF.kraemer.1994.1018">Kraemer et al 1994</a>, <a class="bk_pop" href="#xp.REF.bradford.2011.168">Bradford et al 2011</a>].</p><p><b>Causes of death</b>. The most common causes of death were skin cancer (34%, n=10); neurologic degeneration (31%, n=9); and internal cancer (17%, n=5). The median age at death (29 years) in persons with XP with neurodegeneration was younger than that in persons with XP without neurodegeneration (37 years) (p=0.02).</p></div><div id="xp.Phenotype_Correlations_by_Gene"><h3>Phenotype Correlations by Gene</h3><p>For the overall clinical disorders (XP, Cockayne syndrome [CS], trichothiodystrophy [TTD], cerebrooculofacioskeletal [COFS] syndrome, and others [see <a class="figpopup" href="/books/NBK1397/figure/xp.F1/?report=objectonly" target="object" rid-figpopup="figxpF1" rid-ob="figobxpF1">Figure 1</a>]), the clinical phenotypes are related within broad groups to the specific <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> that is mutated (see <a class="figpopup" href="/books/NBK1397/figure/xp.F1/?report=objectonly" target="object" rid-figpopup="figxpF1" rid-ob="figobxpF1">Figure 1</a> and <a class="figpopup" href="/books/NBK1397/table/xp.T.phenotype_correlations_by_gene_in_x/?report=objectonly" target="object" rid-figpopup="figxpTphenotypecorrelationsbygeneinx" rid-ob="figobxpTphenotypecorrelationsbygeneinx">Table 2</a>).</p><div id="xp.T.phenotype_correlations_by_gene_in_x" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Phenotype Correlations by Gene in XP and Related Disorders</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1397/table/xp.T.phenotype_correlations_by_gene_in_x/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__xp.T.phenotype_correlations_by_gene_in_x_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene</th><th id="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cutaneous Neoplasia</th><th id="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Phenotype</th></tr></thead><tbody><tr><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>DDB2</i></td><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+&#x000a0;<sup>1</sup></td><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XP with no neurologic abnormalities</td></tr><tr><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ERCC1</i></td><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">COFS syndrome&#x000a0;<sup>2</sup></td></tr><tr><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_1" rowspan="5" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>ERCC2</i>&#x000a0;<sup>3</sup></td><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XP w/neurologic abnormalities ranging from none to severe</td></tr><tr><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XP/CS</td></tr><tr><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XP/TTD</td></tr><tr><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">TTD</td></tr><tr><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">COFS syndrome</td></tr><tr><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>ERCC3</i>&#x000a0;<sup>4</sup></td><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XP/CS</td></tr><tr><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">TTD</td></tr><tr><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XP with mild neurologic abnormalities</td></tr><tr><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ERCC4</i></td><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XP with no neurologic abnormalities or severe late-onset neurologic abnormalities&#x000a0;<sup>5</sup>; Fanconi anemia (FA)&#x000a0;<sup>6</sup>; 1 individual with features of XP, CS, and FA, and 2 individuals w/CS&#x000a0;<sup>7</sup></td></tr><tr><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>ERCC5</i></td><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XP w/no neurologic abnormalities or severe neurologic abnormalities</td></tr><tr><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XP/CS</td></tr><tr><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>POLH</i></td><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XP w/no neurologic abnormalities&#x000a0;<sup>8</sup></td></tr><tr><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>XPA</i></td><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XP w/neurologic abnormalities ranging from mild to severe</td></tr><tr><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>XPC</i></td><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_xp.T.phenotype_correlations_by_gene_in_x_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XP w/no neurologic abnormalities&#x000a0;<sup>9,&#x000a0;10</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">COFS = cerebrooculofacioskeletal</p></div></dd><dt></dt><dd><div><p class="no_margin">XP/CS = xeroderma pigmentosum-Cockayne syndrome complex</p></div></dd><dt></dt><dd><div><p class="no_margin">XP/TTD = trichothiodystrophy with XP</p></div></dd><dt></dt><dd><div><p class="no_margin">TTD = trichothiodystrophy (without XP)</p></div></dd><dt>1. </dt><dd><div id="xp.TF.2.1"><p class="no_margin">Adults with large numbers of skin cancers have been reported [<a class="bk_pop" href="#xp.REF.oh.2011.785">Oh et al 2011</a>, <a class="bk_pop" href="#xp.REF.fassihi.2016.e1236">Fassihi et al 2016</a>].</p></div></dd><dt>2. </dt><dd><div id="xp.TF.2.2"><p class="no_margin">Only one person with COFS syndrome has been reported to have <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>ERCC1</i> [<a class="bk_pop" href="#xp.REF.jaspers.2007.457">Jaspers et al 2007</a>]. One individual with a <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> <i>ERCC1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> had severe Cockayne syndrome type II and died at age 2.5 years [<a class="bk_pop" href="#xp.REF.kashiyama.2013.807">Kashiyama et al 2013</a>].</p></div></dd><dt>3. </dt><dd><div id="xp.TF.2.3"><p class="no_margin">Individuals with XP caused by mutation of <i>ERCC2</i> (XP-D) have XP, XP with neurologic abnormalities, the XP/CS complex, TTD, or XP/TTD [<a class="bk_pop" href="#xp.REF.broughton.2001.2539">Broughton et al 2001</a>, <a class="bk_pop" href="#xp.REF.lehmann.2001.15">Lehmann 2001</a>, <a class="bk_pop" href="#xp.REF.fassihi.2016.e1236">Fassihi et al 2016</a>].</p></div></dd><dt>4. </dt><dd><div id="xp.TF.2.4"><p class="no_margin"><a class="bk_pop" href="#xp.REF.robbins.1974.221">Robbins et al [1974]</a>, <a class="bk_pop" href="#xp.REF.weeda.1997.320">Weeda et al [1997]</a>, <a class="bk_pop" href="#xp.REF.oh.2006.1092">Oh et al [2006]</a>, <a class="bk_pop" href="#xp.REF.fassihi.2016.e1236">Fassihi et al [2016]</a>.</p></div></dd><dt>5. </dt><dd><div id="xp.TF.2.5"><p class="no_margin">Most individuals are from Japan. Several have been seen in UK [<a class="bk_pop" href="#xp.REF.fassihi.2016.e1236">Fassihi et al 2016</a>].</p></div></dd><dt>6. </dt><dd><div id="xp.TF.2.6"><p class="no_margin"><a class="bk_pop" href="#xp.REF.bogliolo.2013.800">Bogliolo et al [2013]</a></p></div></dd><dt>7. </dt><dd><div id="xp.TF.2.7"><p class="no_margin"><a class="bk_pop" href="#xp.REF.kashiyama.2013.807">Kashiyama et al [2013]</a></p></div></dd><dt>8. </dt><dd><div id="xp.TF.2.8"><p class="no_margin">Individuals with XP variant are clinically identical to other individuals with XP with cutaneous symptoms without neurologic abnormalities [<a class="bk_pop" href="#xp.REF.inui.2008.2055">Inui et al 2008</a>, <a class="bk_pop" href="#xp.REF.fassihi.2016.e1236">Fassihi et al 2016</a>].</p></div></dd><dt>9. </dt><dd><div id="xp.TF.2.9"><p class="no_margin">"XP neurologic abnormalities" refers to progressive loss of motor, sensory, and cognitive function thought to result from neuronal loss.</p></div></dd><dt>10. </dt><dd><div id="xp.TF.2.10"><p class="no_margin">Most individuals with XP caused by mutation of <i>XPC</i> (XP-C) have XP without XP neurologic abnormalities [<a class="bk_pop" href="#xp.REF.cleaver.1999.9">Cleaver et al 1999</a>, <a class="bk_pop" href="#xp.REF.bradford.2011.168">Bradford et al 2011</a>, <a class="bk_pop" href="#xp.REF.fassihi.2016.e1236">Fassihi et al 2016</a>].</p></div></dd></dl></div></div></div></div><div id="xp.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>The study of <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> is ongoing. Further information is included in literature-based reviews and <a href="http://www.nature.com/ejhg/journal/v22/n7/full/ejhg2013233a.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Clinical Utility Gene Card</a> [<a class="bk_pop" href="#xp.REF.cleaver.1999.9">Cleaver et al 1999</a>, <a class="bk_pop" href="#xp.REF.schubert.2014.22">Schubert et al 2014</a>, <a class="bk_pop" href="#xp.REF.fassihi.2016.e1236">Fassihi et al 2016</a>].</p></div><div id="xp.Nomenclature"><h3>Nomenclature</h3><p>Xeroderma pigmentosum was first described in Vienna by Moriz Kaposi in the textbook of dermatology he published in 1870 with his father-in-law, Ferdinand Hebra. The disorder was first called xeroderma or parchment skin. See discussion in <a class="bk_pop" href="#xp.REF.kraemer.1987.241">Kraemer et al [1987]</a> and in <a class="bk_pop" href="#xp.REF.digiovanna.2012.785">DiGiovanna &#x00026; Kraemer [2012]</a>.</p><p>Previously, an individual with XP with any neurologic abnormality was said to have the DeSanctis-Cacchione syndrome. With clarification of the spectrum of XP disease, this term is now reserved for XP with severe neurologic disease with dwarfism and immature sexual development. The complete DeSanctis-Cacchione syndrome has been recognized in very few individuals; however, many individuals with XP have one or more of its neurologic features.</p><p>"Pigmented xerodermoid" is now known to be identical to the XP variant.</p><p>Before the genes responsible for XP were identified, complementation groups were used to categorize functional defects in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. In an XP complementation analysis cells from affected individuals were fused in the laboratory to determine whether their defects were different, in which case they would be able to supply all functions necessary to restore a normal cellular <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Complementation is therefore a test of function and enabled the categorization of affected individuals as having the same or different defects. Subsequently, each complementation group was found to result from a defect in a distinct <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> (<a class="figpopup" href="/books/NBK1397/table/xp.T.xpassociated_genes_and_their_comple/?report=objectonly" target="object" rid-figpopup="figxpTxpassociatedgenesandtheircomple" rid-ob="figobxpTxpassociatedgenesandtheircomple">Table 3</a>). Testing to assign complementation group is currently not commercially available.</p><div id="xp.T.xpassociated_genes_and_their_comple" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>XP-Associated Genes and Their Complementation Groups</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1397/table/xp.T.xpassociated_genes_and_their_comple/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__xp.T.xpassociated_genes_and_their_comple_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_xp.T.xpassociated_genes_and_their_comple_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene</th><th id="hd_h_xp.T.xpassociated_genes_and_their_comple_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Complementation Group&#x000a0;<sup>1</sup></th></tr></thead><tbody><tr><td headers="hd_h_xp.T.xpassociated_genes_and_their_comple_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>DDB2</i></td><td headers="hd_h_xp.T.xpassociated_genes_and_their_comple_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">E</td></tr><tr><td headers="hd_h_xp.T.xpassociated_genes_and_their_comple_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ERCC1</i></td><td headers="hd_h_xp.T.xpassociated_genes_and_their_comple_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 2</td></tr><tr><td headers="hd_h_xp.T.xpassociated_genes_and_their_comple_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ERCC2</i></td><td headers="hd_h_xp.T.xpassociated_genes_and_their_comple_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">D</td></tr><tr><td headers="hd_h_xp.T.xpassociated_genes_and_their_comple_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ERCC3</i></td><td headers="hd_h_xp.T.xpassociated_genes_and_their_comple_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">B</td></tr><tr><td headers="hd_h_xp.T.xpassociated_genes_and_their_comple_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ERCC4</i></td><td headers="hd_h_xp.T.xpassociated_genes_and_their_comple_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">F</td></tr><tr><td headers="hd_h_xp.T.xpassociated_genes_and_their_comple_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ERCC5</i></td><td headers="hd_h_xp.T.xpassociated_genes_and_their_comple_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">G</td></tr><tr><td headers="hd_h_xp.T.xpassociated_genes_and_their_comple_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>POLH</i></td><td headers="hd_h_xp.T.xpassociated_genes_and_their_comple_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variant</td></tr><tr><td headers="hd_h_xp.T.xpassociated_genes_and_their_comple_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>XPA</i></td><td headers="hd_h_xp.T.xpassociated_genes_and_their_comple_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">A</td></tr><tr><td headers="hd_h_xp.T.xpassociated_genes_and_their_comple_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>XPC</i></td><td headers="hd_h_xp.T.xpassociated_genes_and_their_comple_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">C</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="xp.TF.3.1"><p class="no_margin"><a class="bk_pop" href="#xp.REF.digiovanna.2012.785">DiGiovanna &#x00026; Kraemer [2012]</a></p></div></dd><dt>2. </dt><dd><div id="xp.TF.3.2"><p class="no_margin">Previously called group H, a designation that was subsequently withdrawn</p></div></dd></dl></div></div></div></div><div id="xp.Prevalence"><h3>Prevalence</h3><p>Prevalence is estimated at 1:1,000,000 in the United States and Europe [<a class="bk_pop" href="#xp.REF.kleijer.2008.744">Kleijer et al 2008</a>].</p><p>Certain populations have a higher prevalence:</p><ul><li class="half_rhythm"><div>In Japan prevalence is estimated at 1:22,000 [<a class="bk_pop" href="#xp.REF.hirai.2006.171">Hirai et al 2006</a>].</div></li><li class="half_rhythm"><div>In North Africa (Tunisia, Algeria, Morocco, Libya, and Egypt [<a class="bk_pop" href="#xp.REF.ben_rekaya.2009.426">Ben Rekaya et al 2009</a>, <a class="bk_pop" href="#xp.REF.messaoud.2010.883">Messaoud et al 2010</a>, <a class="bk_pop" href="#xp.REF.soufir.2010.1537">Soufir et al 2010</a>] and the Middle East (Turkey, Israel, and Syria) [<a class="bk_pop" href="#xp.REF.kraemer.1985.33">Kraemer &#x00026; Slor 1985</a>, <a class="bk_pop" href="#xp.REF.jerbi.2016.439">Jerbi et al 2016</a>] prevalence is increased, especially in communities in which <a class="def" href="/books/n/gene/glossary/def-item/consanguinity/">consanguinity</a> is common.</div></li></ul></div></div><div id="xp.Genetically_Related_Allelic_Disorders"><h2 id="_xp_Genetically_Related_Allelic_Disorders_">Genetically Related (Allelic) Disorders</h2><p>In addition to XP phenotypes discussed in this <i>GeneReview</i>, pathogenic variants in the genes causing XP are associated with the phenotypes cerebrooculofacioskeletal (COFS) syndrome, Cockayne syndrome, Fanconi anemia (FA), trichothiodystrophy (TTD), and XFE progeroid syndrome (<a class="figpopup" href="/books/NBK1397/figure/xp.F1/?report=objectonly" target="object" rid-figpopup="figxpF1" rid-ob="figobxpF1">Figure 1</a>).</p><div id="xp.T.allelic_disorders" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Allelic Disorders</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1397/table/xp.T.allelic_disorders/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__xp.T.allelic_disorders_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_xp.T.allelic_disorders_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XP-Related Gene</th><th id="hd_h_xp.T.allelic_disorders_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Allelic Disorder</th><th id="hd_h_xp.T.allelic_disorders_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Clinical Features</th></tr></thead><tbody><tr><td headers="hd_h_xp.T.allelic_disorders_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ERCC2</i><br /><i>ERCC5</i></td><td headers="hd_h_xp.T.allelic_disorders_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cerebrooculofacioskeletal syndrome (Pena-Shokeir syndrome, type II; OMIM <a href="http://omim.org/phenotypicSeries/PS214150" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PS214150</a>)</td><td headers="hd_h_xp.T.allelic_disorders_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See <a href="#xp.Differential_Diagnosis">Differential Diagnosis</a></td></tr><tr><td headers="hd_h_xp.T.allelic_disorders_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ERCC1</i>&#x000a0;<sup>1</sup><br /><i>ERCC4</i>&#x000a0;<sup>1</sup></td><td headers="hd_h_xp.T.allelic_disorders_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/cockayne/">Cockayne syndrome</a></td><td headers="hd_h_xp.T.allelic_disorders_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See <a href="#xp.Differential_Diagnosis">Differential Diagnosis</a></td></tr><tr><td headers="hd_h_xp.T.allelic_disorders_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ERCC4</i></td><td headers="hd_h_xp.T.allelic_disorders_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/fa/">Fanconi anemia</a></td><td headers="hd_h_xp.T.allelic_disorders_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Heterogeneous condition characterized by physical abnormalities, bone marrow failure, and increased risk for malignancy</td></tr><tr><td headers="hd_h_xp.T.allelic_disorders_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ERCC3</i><br /><i>ERCC2</i></td><td headers="hd_h_xp.T.allelic_disorders_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Trichothiodystrophy (OMIM <a href="http://omim.org/phenotypicSeries/PS601675" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PS601675</a>)</td><td headers="hd_h_xp.T.allelic_disorders_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See <a href="#xp.Differential_Diagnosis">Differential Diagnosis</a></td></tr><tr><td headers="hd_h_xp.T.allelic_disorders_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ERCC4</i></td><td headers="hd_h_xp.T.allelic_disorders_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XFE progeroid syndrome (OMIM <a href="http://omim.org/entry/610965" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">610965</a>)</td><td headers="hd_h_xp.T.allelic_disorders_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 2</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="xp.TF.4.1"><p class="no_margin">Two individuals with Cockayne syndrome and one individual with phenotypic features of Cockayne syndrome, xeroderma pigmentosum, and Fanconi anemia were described who had <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in either <i>ERCC1</i> or <i>ERCC4</i> [<a class="bk_pop" href="#xp.REF.kashiyama.2013.807">Kashiyama et al 2013</a>].</p></div></dd><dt>2. </dt><dd><div id="xp.TF.4.2"><p class="no_margin"><a class="bk_pop" href="#xp.REF.niedernhofer.2006.1038">Niedernhofer et al [2006]</a> described a male age 15 years with cachexia, dwarfism, and microcephaly, marked sun sensitivity from birth, visual impairment due to optic atrophy, hearing loss, mild learning disabilities, progressive growth failure, facial features characteristic of premature aging, mild ataxia, and poor coordination. <a class="bk_pop" href="#xp.REF.niedernhofer.2006.1038">Niedernhofer et al [2006]</a> proposed that this represented a new progeroid syndrome. Whether XFE progeroid syndrome represents a distinct condition or is part of the spectrum of XP, FA, or XP/CS has not been determined.</p></div></dd></dl></div></div></div><p><b>Sporadic tumors.</b> Investigation of the association between an increased cancer risk and heterozygosity for an allelic variant causing XP is an active area of research.</p></div><div id="xp.Differential_Diagnosis"><h2 id="_xp_Differential_Diagnosis_">Differential Diagnosis</h2><p>Xeroderma pigmentosum (XP), XP with neurologic abnormalities, Cockayne syndrome (CS), the XP/CS complex, trichothiodystrophy (TTD), the XP/TTD complex, cerebrooculofacioskeletal (COFS) syndrome, COFS/TTD, CS/TTD complex, and the UV-sensitive syndrome [<a class="bk_pop" href="#xp.REF.horibata.2004.15410">Horibata et al 2004</a>, <a class="bk_pop" href="#xp.REF.berneburg.2007">Berneburg &#x00026; Kraemer 2007</a>, <a class="bk_pop" href="#xp.REF.kraemer.2007.1388">Kraemer et al 2007</a>, <a class="bk_pop" href="#xp.REF.stefanini.2008">Stefanini &#x00026; Kraemer 2008</a>, <a class="bk_pop" href="#xp.REF.kraemer.2012">Kraemer &#x00026; Ruenger 2012</a>, <a class="bk_pop" href="#xp.REF.ruenger.2012">Ruenger et al 2012</a>] represent ten genetic diseases that exhibit cutaneous photosensitivity caused by defective nucleotide excision repair (NER). They are associated with defects in 13 different genes (see <a class="figpopup" href="/books/NBK1397/figure/xp.F1/?report=objectonly" target="object" rid-figpopup="figxpF1" rid-ob="figobxpF1">Figure 1</a>).</p><div id="xp.T.autosomal_recessive_nucleotide_exci" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p>Autosomal Recessive Nucleotide Excision Repair Disorders Exhibiting Cutaneous Photosensitivity</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1397/table/xp.T.autosomal_recessive_nucleotide_exci/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__xp.T.autosomal_recessive_nucleotide_exci_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_xp.T.autosomal_recessive_nucleotide_exci_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Phenotype&#x000a0;<sup>1</sup></th><th id="hd_h_xp.T.autosomal_recessive_nucleotide_exci_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene(s)</th><th id="hd_h_xp.T.autosomal_recessive_nucleotide_exci_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Clinical Features</th></tr></thead><tbody><tr><td headers="hd_h_xp.T.autosomal_recessive_nucleotide_exci_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cerebrooculofacioskeletal (COFS) syndrome (Pena-Shokeir syndrome, type II; OMIM <a href="http://omim.org/phenotypicSeries/PS214150" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PS214150</a>)</td><td headers="hd_h_xp.T.autosomal_recessive_nucleotide_exci_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ERCC2</i>&#x000a0;<sup>2</sup><br /><i>ERCC5</i>&#x000a0;<sup>2</sup><br /><i>ERCC6</i>&#x000a0;<sup>3</sup></td><td headers="hd_h_xp.T.autosomal_recessive_nucleotide_exci_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Progressive neurologic disorder marked by microcephaly w/intracranial calcifications &#x00026; growth failure.<br />Ocular findings of microcornea, cataracts, &#x00026; optic atrophy are present along w/<a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> joint contractures.<br />Photosensitivity may occur w/a concurrent cellular <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of UV sensitivity.</td></tr><tr><td headers="hd_h_xp.T.autosomal_recessive_nucleotide_exci_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/cockayne/">Cockayne syndrome</a> (CS)</td><td headers="hd_h_xp.T.autosomal_recessive_nucleotide_exci_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ERCC6</i><br /><i>ERCC8</i>&#x000a0;<sup>4</sup></td><td headers="hd_h_xp.T.autosomal_recessive_nucleotide_exci_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">CS type I: Normal prenatal growth w/onset of growth &#x00026; developmental abnormalities in the first 2 years. By the time the disease has become fully manifest, height, weight, &#x00026; head circumference are far below the 5th percentile. Progressive impairment of vision, hearing,&#x00026; central &#x00026; peripheral nervous system function lead to severe disability. Death typically occurs in the 1st or 2nd decade.<br />As in XP, cells from individuals w/CS are hypersensitive to killing by UV; however, CS cells have normal post-UV unscheduled DNA synthesis (UDS). CS cells also have delayed recovery of RNA synthesis after UV exposure, reflecting their deficiency in transcription-coupled nucleotide excision repair (TC-NER).</td></tr><tr><td headers="hd_h_xp.T.autosomal_recessive_nucleotide_exci_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Trichothiodystrophy (TTD; OMIM <a href="http://omim.org/phenotypicSeries/PS601675" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PS601675</a>)</td><td headers="hd_h_xp.T.autosomal_recessive_nucleotide_exci_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ERCC3</i>&#x000a0;<sup>2</sup><br /><i>ERCC2</i>&#x000a0;<sup>2</sup><br /><i>GTF2H5</i><br /><i>MPLKIP</i>&#x000a0;<sup>5</sup><br /><i>GTF2E2&#x000a0;<sup>6</sup></i></td><td headers="hd_h_xp.T.autosomal_recessive_nucleotide_exci_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variable <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> including photosensitivity, ichthyosis, brittle hair w/"tiger tail" appearance under polarizing microscopy&#x000a0;<sup>7</sup>, intellectual impairment, short stature, microcephaly, dysmyelination of the brain, &#x00026; the characteristic facial features of protruding ears &#x00026; micrognathia<br />20-fold increased risk of death before age 10 years, primarily from infections&#x000a0;<sup>8</sup><br />Frequency of pregnancy complications &#x00026; neonatal abnormalities is increased in TTD but not in mothers w/XP who have different pathogenic variants in the same <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> (<i>ERCC2</i>)&#x000a0;<sup>9</sup></td></tr><tr><td headers="hd_h_xp.T.autosomal_recessive_nucleotide_exci_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XP/CS complex</td><td headers="hd_h_xp.T.autosomal_recessive_nucleotide_exci_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ERCC2&#x000a0;<sup>2</sup></i><br /><i>ERCC3</i>&#x000a0;<sup>2</sup><br /><i>ERCC4</i>&#x000a0;<sup>2</sup><br /><i>ERCC5</i>&#x000a0;<sup>10,&#x000a0;11</sup></td><td headers="hd_h_xp.T.autosomal_recessive_nucleotide_exci_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Facial freckling &#x00026; early skin cancers typical of XP &#x00026; some features of CS (e.g., intellectual disability, spasticity, short stature, hypogonadism) but not skeletal dysplasia. In contrast to XP, in which neuronal degeneration predominates, dysmyelination typical of CS is observed in XP/CS.</td></tr><tr><td headers="hd_h_xp.T.autosomal_recessive_nucleotide_exci_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">COFS/TTD</td><td headers="hd_h_xp.T.autosomal_recessive_nucleotide_exci_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ERCC2</i>&#x000a0;<sup>12</sup></td><td headers="hd_h_xp.T.autosomal_recessive_nucleotide_exci_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Combined features of COFS &#x00026; TTD</td></tr><tr><td headers="hd_h_xp.T.autosomal_recessive_nucleotide_exci_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">CS/TTD complex</td><td headers="hd_h_xp.T.autosomal_recessive_nucleotide_exci_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ERCC2</i>&#x000a0;<sup>12</sup></td><td headers="hd_h_xp.T.autosomal_recessive_nucleotide_exci_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Combined features of CS &#x00026; TTD</td></tr><tr><td headers="hd_h_xp.T.autosomal_recessive_nucleotide_exci_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">UV-sensitive syndrome</td><td headers="hd_h_xp.T.autosomal_recessive_nucleotide_exci_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ERCC6</i>&#x000a0;<sup>13</sup><br /><i>ERCC8</i>&#x000a0;<sup>13</sup><br /><i>UVSSA</i>&#x000a0;<sup>13</sup></td><td headers="hd_h_xp.T.autosomal_recessive_nucleotide_exci_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mild photosensitivity w/out pigmentary abnormalities or apparent defects in the central nervous system. Cells from <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have the same transcription defects as those in individuals w/CS.</td></tr><tr><td headers="hd_h_xp.T.autosomal_recessive_nucleotide_exci_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XP/TTD complex</td><td headers="hd_h_xp.T.autosomal_recessive_nucleotide_exci_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ERCC2</i>&#x000a0;<sup>14</sup></td><td headers="hd_h_xp.T.autosomal_recessive_nucleotide_exci_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Phenotypic features of TTD w/the clinical &#x00026; cellular <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of XP. Unlike most people w/TTD, those w/XP/TTD may experience increased frequency of skin cancers.</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a></p></div></dd><dt></dt><dd><div><p class="no_margin">AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a></p></div></dd><dt>1. </dt><dd><div id="xp.TF.5.1"><p class="no_margin">See hyperlinked <i>GeneReview</i>, OMIM <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> entry, or cited reference for more information.</p></div></dd><dt>2. </dt><dd><div id="xp.TF.5.2"><p class="no_margin">Allelic with XP</p></div></dd><dt>3. </dt><dd><div id="xp.TF.5.3"><p class="no_margin"><a class="bk_pop" href="#xp.REF.meira.2000.1221">Meira et al [2000]</a>, <a class="bk_pop" href="#xp.REF.graham.2001.291">Graham et al [2001]</a></p></div></dd><dt>4. </dt><dd><div id="xp.TF.5.4"><p class="no_margin">Two individuals with Cockayne syndrome and one individual with phenotypic features of Cockayne syndrome, xeroderma pigmentosum, and Fanconi anemia had <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in either <i>ERCC1</i> or <i>ERCC4</i> [<a class="bk_pop" href="#xp.REF.kashiyama.2013.807">Kashiyama et al 2013</a>].</p></div></dd><dt>5. </dt><dd><div id="xp.TF.5.5"><p class="no_margin"><a class="bk_pop" href="#xp.REF.broughton.2001.2539">Broughton et al [2001]</a>, <a class="bk_pop" href="#xp.REF.itin.2001.891">Itin et al [2001]</a>, <a class="bk_pop" href="#xp.REF.bootsma.2002">Bootsma et al [2002]</a>, <a class="bk_pop" href="#xp.REF.gigliamari.2004.714">Giglia-Mari et al [2004]</a>, <a class="bk_pop" href="#xp.REF.liang.2005.224">Liang et al [2005]</a>, <a class="bk_pop" href="#xp.REF.kraemer.2007.1388">Kraemer et al [2007]</a>, <a class="bk_pop" href="#xp.REF.heller.2015.734">Heller et al [2015]</a></p></div></dd><dt>6. </dt><dd><div id="xp.TF.5.6"><p class="no_margin"><a class="bk_pop" href="#xp.REF.kuschal.2016.627">Kuschal et al [2016]</a></p></div></dd><dt>7. </dt><dd><div id="xp.TF.5.7"><p class="no_margin"><a class="bk_pop" href="#xp.REF.liang.2005.224">Liang et al [2005]</a></p></div></dd><dt>8. </dt><dd><div id="xp.TF.5.8"><p class="no_margin"><a class="bk_pop" href="#xp.REF.faghri.2008.609">Faghri et al [2008]</a></p></div></dd><dt>9. </dt><dd><div id="xp.TF.5.9"><p class="no_margin"><a class="bk_pop" href="#xp.REF.moslehi.2010.365">Moslehi et al [2010]</a>, <a class="bk_pop" href="#xp.REF.tamura.2011.1046">Tamura et al [2011]</a>, <a class="bk_pop" href="#xp.REF.tamura.2012.1308">Tamura et al [2012]</a></p></div></dd><dt>10. </dt><dd><div id="xp.TF.5.10"><p class="no_margin">See <a class="figpopup" href="/books/NBK1397/table/xp.T.phenotype_correlations_by_gene_in_x/?report=objectonly" target="object" rid-figpopup="figxpTphenotypecorrelationsbygeneinx" rid-ob="figobxpTphenotypecorrelationsbygeneinx">Table 2</a> and <a class="figpopup" href="/books/NBK1397/figure/xp.F1/?report=objectonly" target="object" rid-figpopup="figxpF1" rid-ob="figobxpF1">Figure 1</a>.</p></div></dd><dt>11. </dt><dd><div id="xp.TF.5.11"><p class="no_margin"><a class="bk_pop" href="#xp.REF.kashiyama.2013.807">Kashiyama et al [2013]</a></p></div></dd><dt>12. </dt><dd><div id="xp.TF.5.12"><p class="no_margin">See <a class="bk_pop" href="#xp.REF.digiovanna.2012.785">DiGiovanna &#x00026; Kraemer [2012]</a></p></div></dd><dt>13. </dt><dd><div id="xp.TF.5.13"><p class="no_margin"><a class="bk_pop" href="#xp.REF.itoh.1994.233">Itoh et al [1994]</a>, <a class="bk_pop" href="#xp.REF.horibata.2004.15410">Horibata et al [2004]</a>, <a class="bk_pop" href="#xp.REF.nardo.2009.6209">Nardo et al [2009]</a>, <a class="bk_pop" href="#xp.REF.nakazawa.2012.586">Nakazawa et al [2012]</a>, <a class="bk_pop" href="#xp.REF.schwertman.2012.598">Schwertman et al [2012]</a>, <a class="bk_pop" href="#xp.REF.zhang.2012.593">Zhang et al [2012]</a>, <a class="bk_pop" href="#xp.REF.wilson.2016.773">Wilson et al [2016]</a></p></div></dd><dt>14. </dt><dd><div id="xp.TF.5.14"><p class="no_margin"><a class="bk_pop" href="#xp.REF.broughton.2001.2539">Broughton et al [2001]</a>, <a class="bk_pop" href="#xp.REF.boyle.2008.1194">Boyle et al [2008]</a>, <a class="bk_pop" href="#xp.REF.digiovanna.2012.785">DiGiovanna &#x00026; Kraemer [2012]</a></p></div></dd></dl></div></div></div><div id="xp.Other"><h3>Other</h3><p>In addition to diseases sharing deficient nucleotide excision repair, other diseases exhibiting cutaneous photosensitivity may be considered, especially in cases with a paucity of other clinical findings. These other diseases include the following:</p><ul><li class="half_rhythm"><div><a href="/books/n/gene/rts/">Rothmund-Thomson syndrome</a> and the allelic disorder <a href="/books/n/gene/bgs/">Baller-Gerold syndrome</a></div></li><li class="half_rhythm"><div>Hartnup disorder (OMIM <a href="http://omim.org/entry/234500" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">234500</a>), a disorder of amino acid absorption resulting from <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>SLC6A19</i>, a non-polar amino acid transporter. Affected individuals may have reduced levels of niacin with resulting pellagra-like symptoms of photosensitivity with dermatitis, diarrhea, and dementia. However, individuals with Hartnup disorder are not reported to have increased frequency of skin cancer, as is seen in those with XP.</div></li></ul><p>The cutaneous findings of <a href="/books/n/gene/carney/">Carney complex</a> may be confused with those of XP; however, Carney complex is characterized by lentigines without evidence of the usually associated signs of skin damage such as atrophy and telangiectasia (i.e., poikiloderma) and cutaneous findings are not limited to sun-exposed sites [<a class="bk_pop" href="#xp.REF.correa.2015.m85">Correa et al 2015</a>].</p></div></div><div id="xp.Management"><h2 id="_xp_Management_">Management</h2><div id="xp.Evaluations_Following_Initial_Diagnos"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with xeroderma pigmentosum (XP), the following evaluations are recommended (reviewed in <a class="bk_pop" href="#xp.REF.tamura.2014">Tamura et al [2014]</a>).</p><p><b>Skin</b></p><ul><li class="half_rhythm"><div>Perform baseline examination of the skin (including all sun-exposed as well as sun-shielded areas) for evidence of sunlight-induced damage including pigmentary changes, precancerous lesions, and skin cancers.</div></li><li class="half_rhythm"><div>For examination of the scalp, use a hair dryer (on a cool setting) to blow the hair aside.</div></li><li class="half_rhythm"><div>Examination of the lip and adjacent tip of the tongue for signs of sun damage, including actinic cheilitis (a type of actinic keratosis or leukoplakia occurring on the lips) and prominent telangiectasia, which may precede the development of cancer in these areas [<a class="bk_pop" href="#xp.REF.butt.2010.534">Butt et al 2010</a>].</div></li><li class="half_rhythm"><div>Baseline clinical color photographs of the entire skin surface with close-ups (including a ruler) of individual lesions to facilitate follow-up and detection of early skin cancers.</div></li></ul><p><b>Eyes</b></p><ul><li class="half_rhythm"><div>Examine the lids and anterior UV-exposed portions of the globe for evidence of sun-induced damage including ectropion, entropion, inflammatory masses (pterygia, pinguecula), clouding of the cornea, and cancer of the lids, conjunctiva, or cornea. Eversion of the lids may be necessary to detect cancers of the mucosal surface.</div></li><li class="half_rhythm"><div>Use the Schirmer test to detect dry eyes. This test involves measurement of the extent of absorption of tears into filter paper placed under eyelids for a few minutes [<a class="bk_pop" href="#xp.REF.brooks.2013.1324">Brooks et al 2013</a>].</div></li></ul><p><b>Neurologic</b></p><ul><li class="half_rhythm"><div>Deep tendon reflex testing</div></li><li class="half_rhythm"><div>Measurement of the occipital frontal circumference (OFC), to determine if microcephaly is present</div></li><li class="half_rhythm"><div>MRI of the brain and nerve conduction velocities, if other neurologic problems are detected</div></li></ul><p><b>Auditory.</b> Baseline audiometry evaluation to screen for the sensorineural hearing loss, which may be present as a component of the XP-associated neurologic abnormalities [<a class="bk_pop" href="#xp.REF.totonchy.2013.194">Totonchy et al 2013</a>]</p><p><b>Genetic.</b> Consultation with a clinical geneticist and/or genetic counselor</p></div><div id="xp.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>The treatment of manifestations is reviewed in <a class="bk_pop" href="#xp.REF.tamura.b">Tamura et al [2010b]</a> and <a class="bk_pop" href="#xp.REF.tamura.2014">Tamura et al [2014]</a>.</p><p><b>Skin.</b> Premalignant lesions (e.g., small actinic keratosis) may be treated by freezing with liquid nitrogen.</p><p>Larger areas of sun-damaged skin can be treated with field treatments such as topical 5-fluorouracil or imiquimod preparations. Rarely, therapeutic dermatome shaving or dermabrasion has been used to remove the more damaged superficial epidermal layers. This procedure permits repopulation by relatively UV-shielded cells from the follicles and glands.</p><p>Cutaneous neoplasms are treated in the same manner as in individuals who do not have XP. This involves electrodesiccation/curettage or surgical excision. Skin cancers which are recurrent or in locations at high risk for recurrence are best treated with Mohs micrographic surgery. Because multiple surgical procedures are often necessary, removal of undamaged skin should be minimized. Severe cases have been treated by excision of large portions of the facial surface and grafting with sun-protected skin.</p><p>While individuals with XP are not abnormally sensitive to therapeutic x-rays, and individuals with XP have responded normally to full-dose therapeutic x-radiation for treatment of inoperable neoplasms [<a class="bk_pop" href="#xp.REF.digiovanna.1998.153">DiGiovanna et al 1998</a>], cultured cells from a few individuals with XP were found to be hypersensitive to x-radiation [<a class="bk_pop" href="#xp.REF.arlett.2006.510">Arlett et al 2006</a>]. When x-radiation therapy is indicated, an initial small dose is advisable to test for clinical hypersensitivity.</p><p>Oral isotretinoin or acitretin can be effective in preventing new neoplasms in individuals with multiple skin cancers [<a class="bk_pop" href="#xp.REF.kraemer.1988.1633">Kraemer et al 1988</a>]. Because of its toxicity (hepatic, hyperlipidemic, and teratogenic effects; calcification of ligaments and tendons; premature closure of the epiphyses), oral isotretinoin or acitretin should be reserved for individuals with XP who are actively developing large numbers of new tumors. Some individuals may respond to lower doses of isotretinoin or acitretin with less toxicity.</p><p>A few case reports have described regression of skin cancers with use of imiquimod cream in individuals with XP [<a class="bk_pop" href="#xp.REF.giannotti.2003.33">Giannotti et al 2003</a>, <a class="bk_pop" href="#xp.REF.nagore.2003.858">Nagore et al 2003</a>, <a class="bk_pop" href="#xp.REF.roseeuw.2003.30">Roseeuw 2003</a>]; however, no controlled studies have been reported.</p><p><b>Eyes.</b> Methylcellulose eye drops or soft contact lenses have been used to keep the cornea moist and to protect against mechanical trauma in individuals with deformed eyelids.</p><p>Corneal transplantation has restored vision in individuals with severe keratitis with corneal opacity. However, the immunosuppression necessary to prevent rejection of the transplant may increase the risk for skin cancer.</p><p>Neoplasms of the lids, conjunctiva, and cornea are usually treated surgically.</p><p><b>Hearing.</b> Hearing aids can be of great help for individuals who have sensorineural hearing loss with learning difficulties in school (see <a class="bk_pop" href="#xp.REF.totonchy.2013.194">Totonchy et al [2013]</a> and <a href="/books/n/gene/deafness-overview/">Deafness and Hereditary Hearing Loss Overview</a>).</p></div><div id="xp.Prevention_of_Primary_Manifestations"><h3>Prevention of Primary Manifestations</h3><p>Treatment of XP depends on early diagnosis and immediate, aggressive avoidance of sun and other UV exposure. This involves avoiding or minimizing outdoor exposure at times when UV radiation is present (when the sun is out or during daytime through clouds).</p><p>Clinical suspicion of XP should prompt immediate sun-protective measures until the diagnosis is confirmed or an alternative explanation is determined.</p><p>Individuals should be educated to protect all body surfaces from UV radiation by wearing protective clothing including hats, long sleeves, long pants and gloves, broad-spectrum, high sun-protective factor (SPF) sunscreens, UV-absorbing glasses, and long hair styles. The eyes should be protected by wearing UV-absorbing glasses with side shields. Some individuals have custom-made hats with UV-absorbing face shields to permit visibility outdoors while protecting the face from UV.</p><p>Because the cells of individuals with XP are hypersensitive to UVA and UVB (found in sunlight) and UVC (found in some artificial light sources), it is useful to measure UV light in an individual's home, school, or work environment with a light meter so that high levels of environmental UV (e.g., halogen lamps) can be identified and eliminated if possible. While no standards exist for perfectly safe UV exposure in individuals with XP, the use of UV meters can alert individuals to unexpected sources of high levels of environmental UV.</p></div><div id="xp.Prevention_of_Secondary_Complications"><h3>Prevention of Secondary Complications</h3><p>Vitamin D is produced in the skin by a reaction involving exposure to UV radiation. Active adults with XP and skin cancers received sufficient vitamin D in their diet in the past to result in normal serum concentrations of the active form (1,25 dihydroxy vitamin D) [<a class="bk_pop" href="#xp.REF.sollitto.1997.942">Sollitto et al 1997</a>]. However, children protected from sunlight very early in life have had low serum concentration of 25 hydroxy vitamin D; one child became susceptible to bone fractures [<a class="bk_pop" href="#xp.REF.ali.2009.442">Ali et al 2009</a>; Author, personal observation]. Dietary supplementation with oral vitamin D is recommended for persons with low serum concentration of serum vitamin D [<a class="bk_pop" href="#xp.REF.reichrath.2007.664">Reichrath 2007</a>; Author, personal communication].</p></div><div id="xp.Surveillance"><h3>Surveillance</h3><p>See <a class="bk_pop" href="#xp.REF.tamura.b">Tamura et al [2010b]</a> and <a class="bk_pop" href="#xp.REF.tamura.2014">Tamura et al [2014]</a>.</p><p><b>Skin.</b> A physician should examine the skin of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual at frequent intervals (every ~3-12 months, depending on the severity of skin disease).</p><p>Affected individuals or their parents should be educated to look for abnormal pigmented lesions or the appearance of basal cell or squamous cell carcinoma. Individuals should be examined frequently by a family member who has been instructed in recognition of cutaneous neoplasms.</p><p><b>Eyes</b> should be examined regularly for signs of UV exposure and damage.</p><p><b>Neurologic.</b> Routine neurologic examination is indicated because of progressive neurologic abnormalities that are present in a minority of individuals with XP and may not be detected in young children.</p><p><b>Hearing.</b> Periodic audiograms. Serial audiograms at regular intervals may also be useful for assessing the presence or absence of progressive neurologic degeneration, especially in those with a history of acute burning on minimal sun exposure [<a class="bk_pop" href="#xp.REF.totonchy.2013.194">Totonchy et al 2013</a>].</p></div><div id="xp.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>UV exposure from sunlight and artificial sources of UV radiation should be avoided (see <a href="#xp.Prevention_of_Primary_Manifestations">Prevention of Primary Manifestations</a>).</p><p><b>Artificial sources of UV.</b> Certain light sources (e.g., mercury arc, halogen, and other lamps) can be unrecognized sources of UV. Although such light sources are often shielded, in open areas such as gymnasiums they can be a source of UV if the shield has been breached. UV meters are readily available to enable monitoring of areas to identify unexpected UV sources.</p><p><b>Cigarette smoke.</b> Because cells from individuals with XP are also hypersensitive to environmental mutagens, such as benzo[<i>a</i>]pyrene found in cigarette smoke, prudence dictates that individuals with XP should be protected against these agents. One individual with XP who smoked cigarettes for more than ten years died of bronchogenic carcinoma of the lungs at age 35 years [<a class="bk_pop" href="#xp.REF.kraemer.1994.1018">Kraemer et al 1994</a>]. The authors recently cared for another individual with XP who smoked and developed lung cancer in the fifth decade of life.</p></div><div id="xp.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to evaluate the apparently asymptomatic older and younger sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> in order to identify as early as possible those who would benefit from prompt initiation of treatment and preventive measures.</p><ul><li class="half_rhythm"><div>If the family-specific pathogenic variants have been identified, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> for at-risk sibs is possible.</div></li><li class="half_rhythm"><div>Clinical evaluation to identify <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> may be difficult, especially in an infant or young child. In this case, sun protection may be recommended for sibs until a definitive laboratory diagnosis is obtained.</div></li></ul><p>See <a href="#xp.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="xp.Pregnancy_Management"><h3>Pregnancy Management</h3><p>The systemic retinoids isotretinoin and acitretin are used as skin cancer chemopreventive agents in individuals who are actively developing large numbers of skin cancers, and thus may be used by some women with XP [<a class="bk_pop" href="#xp.REF.kraemer.1988.1633">Kraemer et al 1988</a>]. Systemic retinoids are known to be teratogenic to a developing fetus and pose a high risk for birth defects. Therefore, women who are using systemic retinoids should be appropriately counseled about pregnancy risks and the need for effective contraception; regular monitoring with pregnancy tests is indicated. Systemic retinoids should be administered only by physicians who are knowledgeable regarding their risks and benefits.</p><p>To access isotretinoin in the US, women and their prescribing providers must be enrolled in the <a href="https://www.ipledgeprogram.com/default.aspx" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">iPLEDGE program</a> to minimize the potential for fetal exposure. Pregnancy avoidance is initiated before therapy, continues during therapy, and extends post-treatment until the drug is cleared from the body. While both drugs may be effective in preventing skin cancers, acitretin may take longer to be eliminated from the body, requiring an extended period (3 years) of post-therapy pregnancy avoidance to minimize teratogenic risk.</p></div><div id="xp.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>The bacterial DNA repair enzyme T4 endonuclease V in a topical liposome-containing preparation has been reported to reduce the frequency of new actinic keratoses and basal cell carcinomas in individuals with XP in one research study [<a class="bk_pop" href="#xp.REF.yarosh.2001.926">Yarosh et al 2001</a>]. As of 2016, this treatment is not approved by the US Food and Drug Administration.</p><p>Oral vismodegib (Erivedge<sup>&#x000ae;</sup>), an inhibitor of the hedgehog pathway, has been approved by the FDA for treatment of metastatic basal cell carcinoma or locally advanced basal cell carcinoma that has recurred following surgery. This drug has also been approved for use in individuals with basal cell carcinoma who are not candidates for surgery or for radiation therapy (see <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203388lbl.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FDA package insert</a>). This treatment may be appropriate for some individuals with XP, however, no studies on the efficacy of this drug in those with XP have been published. Oral vismodegib is also a teratogen, leading to embryo-fetal death, midline defects, missing digits, and other birth defects in an exposed embryo or fetus; effective contraception during and after vismodegib treatment is advised in both women and men.</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div><div id="xp.Other_1"><h3>Other</h3><p>Use of cotton swabs to obtain specimens from conjunctival lesions for cytologic examination for malignant cells is being evaluated [<a class="bk_pop" href="#xp.REF.brooks.2013.1324">Brooks et al 2013</a>].</p></div></div><div id="xp.Genetic_Counseling"><h2 id="_xp_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="xp.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Xeroderma pigmentosum (XP) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="xp.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an individual with XP are obligate heterozygotes (i.e., carriers of one XP-related <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) of XP-related pathogenic variants are clinically unaffected.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are clinically unaffected.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The offspring of an individual with XP are obligate heterozygotes (carriers) for an XP-related <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and are clinically unaffected.</div></li><li class="half_rhythm"><div>The offspring of an individual with XP and a clinically unaffected individual <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an XP-related <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> will have a 50% chance of having XP. This is a consideration in populations with a <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a> or with a high rate of <a class="def" href="/books/n/gene/glossary/def-item/consanguinity/">consanguinity</a>.</div></li></ul><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of an XP-related <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="xp.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk relatives requires prior identification of the XP-related pathogenic variants in the family (see <a class="bk_pop" href="#xp.REF.christenzaech.2009.1285">Christen-Zaech et al [2009]</a> for discussion).</p><p>Carrier testing of reproductive partners of known carriers is possible for variants in XP-related genes.</p></div><div id="xp.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#xp.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="xp.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the XP-related pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for XP are possible.</p></div></div><div id="xp.Resources"><h2 id="_xp_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=Xeroderma%20pigmentosum&#x00026;parent=Genetic%20Syndromes&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Xeroderma pigmentosum</a></div></li><li class="half_rhythm"><div><b>Xeroderma Pigmentosum Society, Inc (XP Society)</b></div><div>437 Syndertown Road</div><div>Craryville NY 12521</div><div><b>Phone:</b> 877-XPS-CURE (877-977-2873); 518-851-2612</div><div><b>Email:</b> xps@xps.org</div><div><a href="http://www.xps.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.xps.org</a></div></li><li class="half_rhythm"><div><b>XP Family Support Group</b></div><div>10259 Atlantis Drive</div><div>Elk Grove CA 95624</div><div><b>Phone:</b> 916-628-3814</div><div><b>Email:</b> contact@xpfamilysupport.org</div><div><a href="https://xpfamilysupport.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.xpfamilysupport.org</a></div></li><li class="half_rhythm"><div><b>XP Support Group</b></div><div>Instron House</div><div>Coronation Road</div><div>Bucks HP12 3SY</div><div>United Kingdom</div><div><b>Phone:</b> +44 (0) 1494 456192; +44 (0) 1494 459888</div><div><b>Email:</b> info@xpsupportgroup.org.uk</div><div><a href="http://xpsupportgroup.org.uk/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">xpsupportgroup.org.uk</a></div></li></ul></div><div id="xp.Molecular_Genetics"><h2 id="_xp_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="xp.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Xeroderma Pigmentosum: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1397/table/xp.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__xp.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_xp.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_xp.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_xp.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_xp.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_xp.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_xp.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_xp.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/1643" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>DDB2</i></a></td><td headers="hd_b_xp.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=1643" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">11p11<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_xp.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q92466" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">DNA damage-binding protein 2</a></td><td headers="hd_b_xp.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/DDB2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">DDB2 database</a></td><td headers="hd_b_xp.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=DDB2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">DDB2</a></td><td headers="hd_b_xp.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=DDB2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">DDB2</a></td></tr><tr><td headers="hd_b_xp.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/2067" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>ERCC1</i></a></td><td headers="hd_b_xp.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=2067" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">19q13<wbr style="display:inline-block"></wbr>​.32</a></td><td headers="hd_b_xp.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P07992" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">DNA excision repair protein ERCC-1</a></td><td headers="hd_b_xp.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/ERCC1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ERCC1 database</a></td><td headers="hd_b_xp.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=ERCC1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ERCC1</a></td><td headers="hd_b_xp.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=ERCC1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ERCC1</a></td></tr><tr><td headers="hd_b_xp.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/2068" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>ERCC2</i></a></td><td headers="hd_b_xp.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=2068" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">19q13<wbr style="display:inline-block"></wbr>​.32</a></td><td headers="hd_b_xp.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P18074" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">General transcription and DNA repair factor IIH helicase subunit XPD</a></td><td headers="hd_b_xp.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/ERCC2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ERCC2 @ LOVD</a></td><td headers="hd_b_xp.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=ERCC2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ERCC2</a></td><td headers="hd_b_xp.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=ERCC2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ERCC2</a></td></tr><tr><td headers="hd_b_xp.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/2071" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>ERCC3</i></a></td><td headers="hd_b_xp.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=2071" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">2q14<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_xp.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P19447" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">General transcription and DNA repair factor IIH helicase subunit XPB</a></td><td headers="hd_b_xp.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://xpmutations.org/mutations.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">xpmutations.org (ERCC3)</a><br /><a href="http://databases.lovd.nl/shared/genes/ERCC3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ERCC3 database</a></td><td headers="hd_b_xp.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=ERCC3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ERCC3</a></td><td headers="hd_b_xp.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=ERCC3[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ERCC3</a></td></tr><tr><td headers="hd_b_xp.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/2072" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>ERCC4</i></a></td><td headers="hd_b_xp.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=2072" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">16p13<wbr style="display:inline-block"></wbr>​.12</a></td><td headers="hd_b_xp.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q92889" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">DNA repair endonuclease XPF</a></td><td headers="hd_b_xp.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/ERCC4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ERCC4 database</a></td><td headers="hd_b_xp.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=ERCC4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ERCC4</a></td><td headers="hd_b_xp.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=ERCC4[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ERCC4</a></td></tr><tr><td headers="hd_b_xp.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/2073" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>ERCC5</i></a></td><td headers="hd_b_xp.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=2073" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">13q33<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_xp.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P28715" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">DNA repair protein complementing XP-G cells</a></td><td headers="hd_b_xp.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/ERCC5" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ERCC5 database</a></td><td headers="hd_b_xp.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=ERCC5" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ERCC5</a></td><td headers="hd_b_xp.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=ERCC5[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ERCC5</a></td></tr><tr><td headers="hd_b_xp.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/5429" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>POLH</i></a></td><td headers="hd_b_xp.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=5429" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">6p21<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_xp.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q9Y253" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">DNA polymerase eta</a></td><td headers="hd_b_xp.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/POLH" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">POLH database</a></td><td headers="hd_b_xp.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=POLH" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">POLH</a></td><td headers="hd_b_xp.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=POLH[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">POLH</a></td></tr><tr><td headers="hd_b_xp.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/7507" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>XPA</i></a></td><td headers="hd_b_xp.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=7507" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">9q22<wbr style="display:inline-block"></wbr>​.33</a></td><td headers="hd_b_xp.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P23025" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">DNA repair protein complementing XP-A cells</a></td><td headers="hd_b_xp.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://xpmutations.org/mutations.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">xpmutations.org (XPA)</a><br /><a href="http://databases.lovd.nl/shared/genes/XPA" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">XPA database</a></td><td headers="hd_b_xp.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=XPA" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">XPA</a></td><td headers="hd_b_xp.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=XPA[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">XPA</a></td></tr><tr><td headers="hd_b_xp.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/7508" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>XPC</i></a></td><td headers="hd_b_xp.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=7508" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">3p25<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_xp.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q01831" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">DNA repair protein complementing XP-C cells</a></td><td headers="hd_b_xp.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/XPC" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">XPC database</a></td><td headers="hd_b_xp.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=XPC" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">XPC</a></td><td headers="hd_b_xp.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=XPC[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">XPC</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="xp.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="xp.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Xeroderma Pigmentosum (<a href="/omim/126340,126380,133510,133520,133530,278700,278720,278730,278740,278750,278760,278780,600811,603968,610651,611153,613208" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1397/table/xp.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__xp.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/126340" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">126340</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXCISION REPAIR, COMPLEMENTING DEFECTIVE, IN CHINESE HAMSTER, 2; ERCC2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/126380" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">126380</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXCISION REPAIR, COMPLEMENTING DEFECTIVE, IN CHINESE HAMSTER, 1; ERCC1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/133510" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">133510</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXCISION REPAIR, COMPLEMENTING DEFECTIVE, IN CHINESE HAMSTER, 3; ERCC3</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/133520" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">133520</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXCISION REPAIR, COMPLEMENTING DEFECTIVE, IN CHINESE HAMSTER, 4; ERCC4</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/133530" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">133530</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXCISION REPAIR, COMPLEMENTING DEFECTIVE, IN CHINESE HAMSTER, 5; ERCC5</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/278700" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">278700</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP A; XPA</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/278720" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">278720</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C; XPC</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/278730" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">278730</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP D; XPD</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/278740" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">278740</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP E</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/278750" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">278750</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XERODERMA PIGMENTOSUM, VARIANT TYPE; XPV</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/278760" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">278760</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP F; XPF</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/278780" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">278780</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP G; XPG</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/600811" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">600811</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DNA DAMAGE-BINDING PROTEIN 2; DDB2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/603968" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">603968</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">POLYMERASE, DNA, ETA; POLH</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/610651" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">610651</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP B; XPB</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/611153" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">611153</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XPA GENE; XPA</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/613208" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">613208</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XPC GENE; XPC</td></tr></tbody></table></div></div><div id="xp.Molecular_Genetic_Pathogenesis"><h3>Molecular Genetic Pathogenesis</h3><p>An intact DNA repair system that senses, excises, and repairs UV-induced dipyrimidine photoproducts and other forms of DNA damage is necessary to prevent replication errors and subsequent tumorigenesis (<a class="figpopup" href="/books/NBK1397/figure/xp.F2/?report=objectonly" target="object" rid-figpopup="figxpF2" rid-ob="figobxpF2">Figure 2</a>) [<a class="bk_pop" href="#xp.REF.digiovanna.2012.785">DiGiovanna &#x00026; Kraemer 2012</a>].</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figxpF2" co-legend-rid="figlgndxpF2"><a href="/books/NBK1397/figure/xp.F2/?report=objectonly" target="object" title="Figure 2. " class="img_link icnblk_img figpopup" rid-figpopup="figxpF2" rid-ob="figobxpF2"><img class="small-thumb" src="/books/NBK1397/bin/xp-Image002.gif" src-large="/books/NBK1397/bin/xp-Image002.jpg" alt="Figure 2. " /></a><div class="icnblk_cntnt" id="figlgndxpF2"><h4 id="xp.F2"><a href="/books/NBK1397/figure/xp.F2/?report=objectonly" target="object" rid-ob="figobxpF2">Figure 2. </a></h4><p class="float-caption no_bottom_margin">Nucleotide excision repair (NER) pathway Modified from DiGiovanna &#x00026; Kraemer [2012]</p></div></div><p>Exposure to UV radiation from sunlight forms cyclobutane dimers or other photoproducts at adjacent pyrimidines, thereby distorting the DNA. Initial lesion recognition in non-transcribed DNA (global genome repair-GGR) is performed by <i>DDB2</i>-encoded protein [<a class="bk_pop" href="#xp.REF.clement.2010.21">Clement et al 2010</a>, <a class="bk_pop" href="#xp.REF.sugasawa.2010.29">Sugasawa 2010</a>]. The <i>XPC</i>-encoded protein binding to the photoproducts is facilitated by the binding of the <i>DDB2</i>-encoded protein. The <i>XPC</i>-encoded protein is complexed with hHR23B and centrin [<a class="bk_pop" href="#xp.REF.sugasawa.2010.29">Sugasawa 2010</a>].</p><p>DNA damage in transcribed genes (transcription coupled repair [TCR]) is marked by stalled RNA polymerase. The CS encoded proteins (along with others) bind to the damage in the transcribed DNA strand.</p><p>In both global genome repair and transcription coupled repair the XPA protein probably functions in conjunction with replication protein A (RPA), and TFIIH. The XPB/ERCC3 and XPD/ERCC2 proteins (helicases which are part of the TFIIH complex) partially unwind the DNA in the region of the damage, thereby exposing the lesion for further processing. The XPF/ERCC4 product, in a complex with ERCC1, makes a single-strand nick at the 5' side of the lesion, while the XPG/ERCC5 product makes a similar nick on the 3' side, resulting in the release of a region of approximately 30 nucleotides containing the damage. The resulting gap is filled by DNA polymerase using the other (undamaged) strand as a template in a process involving proliferating cell nuclear antigen. DNA ligase I seals the region, restoring the original undamaged sequence [<a class="bk_pop" href="#xp.REF.van_steeg.1999.86">van Steeg &#x00026; Kraemer 1999</a>, <a class="bk_pop" href="#xp.REF.bootsma.2002">Bootsma et al 2002</a>].</p><p>The nucleotide excision repair genes (e.g., XPB/<i>ERCC3</i> and XPD/<i>ERCC2</i>) that are part of the basal <a class="def" href="/books/n/gene/glossary/def-item/transcription-factor/">transcription factor</a> TFIIH are essential to life. Mice with knockout of <i>Ercc2</i> do not survive, whereas <i>Xpa</i> and <i>Xpc</i> knockout mice are viable.</p><p>For detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information for the genes listed below, see <a href="/books/NBK1397/#xp.molgen.TA">Table A</a>, <b>Gene</b>.</p><div id="xp.DDB2_XPE"><h4><i>DDB2</i> (<i>XPE</i>)</h4><p><b>Gene structure.</b>
<i>DDB2</i> codes for a 1.8-kb RNA. It comprises ten exons and nine introns (<a href="/nuccore/NM_000107.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000107.2</a>).</p><p><b>Pathogenic variants.</b> Missense, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and frameshift variants have been reported [<a class="bk_pop" href="#xp.REF.nichols.1996.24317">Nichols et al 1996</a>, <a class="bk_pop" href="#xp.REF.rapi_otrin.2003.1507">Rapi&#x00107;-Otrin et al 2003</a>, <a class="bk_pop" href="#xp.REF.fassihi.2016.e1236">Fassihi et al 2016</a>] (see also <a href="http://www.nature.com/ejhg/journal/v22/n7/full/ejhg2013233a.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Clinical Utility Gene Card</a>).</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>DDB2</i> codes for a 48-kd protein of 427 amino acids. <i>DDB2</i> combined with <i>DDB1</i> forms a heterodimer, which, along with <i>XPC</i>, is involved in the initial recognition of UV-induced DNA damage in non-transcribed portions of the genome.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> XP results from absent or <a href="/books/NBK1397/#xp.molgen.TA">inactivated DNA damage-binding protein 2</a>. Loss of the p48 subunit encoded by <i>DDB2</i> results in large numbers of skin cancers without acute burning on minimal sun exposure [<a class="bk_pop" href="#xp.REF.oh.2011.785">Oh et al 2011</a>, <a class="bk_pop" href="#xp.REF.fassihi.2016.e1236">Fassihi et al 2016</a>]. See also <a class="figpopup" href="/books/NBK1397/table/xp.T.phenotype_correlations_by_gene_in_x/?report=objectonly" target="object" rid-figpopup="figxpTphenotypecorrelationsbygeneinx" rid-ob="figobxpTphenotypecorrelationsbygeneinx">Table 2</a>.</p></div><div id="xp.ERCC1"><h4><i>ERCC1</i></h4><p><b>Gene structure.</b>
<i>ERCC1</i> codes for a 1.2-kb <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a>. It comprises eight exons (<a href="/nuccore/NM_001983.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_001983.3</a>).</p><p><b>Pathogenic variants.</b> One individual with COFS syndrome was reported by <a class="bk_pop" href="#xp.REF.jaspers.2007.457">Jaspers et al [2007]</a>. One individual with severe CS was <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> for two pathogenic variants, p.Lys226Ter and p.Phe231Leu, in <i>ERCC1</i> [<a class="bk_pop" href="#xp.REF.kashiyama.2013.807">Kashiyama et al 2013</a>] (see also <a href="http://www.nature.com/ejhg/journal/v22/n7/full/ejhg2013233a.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Clinical Utility Gene Card</a>).</p><div id="xp.T.ercc1_variants_discussed_in_this_ge" class="table"><h3><span class="label">Table 6. </span></h3><div class="caption"><p><i>ERCC1</i> Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1397/table/xp.T.ercc1_variants_discussed_in_this_ge/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__xp.T.ercc1_variants_discussed_in_this_ge_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_xp.T.ercc1_variants_discussed_in_this_ge_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_xp.T.ercc1_variants_discussed_in_this_ge_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_xp.T.ercc1_variants_discussed_in_this_ge_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_xp.T.ercc1_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.676A&#x0003e;T</td><td headers="hd_h_xp.T.ercc1_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Lys226Ter</td><td headers="hd_h_xp.T.ercc1_variants_discussed_in_this_ge_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_202001.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_202001<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="/protein/NP_973730.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_973730<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_xp.T.ercc1_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.693C&#x0003e;G</td><td headers="hd_h_xp.T.ercc1_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Phe231Leu</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>ERCC1</i> codes for a 110-kd protein of 323 amino acids.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> XP results from absent or inactivated DNA excision repair protein ERCC-1.</p></div><div id="xp.ERCC2_XPD"><h4><i>ERCC2</i> (<i>XPD</i>)</h4><p><b>Gene structure.</b>
<i>ERCC2</i> codes for a 2.3-kb <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a>. It comprises 22 exons and 21 introns (<a href="/nuccore/NM_000400.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000400.3</a>).</p><p><b>Pathogenic variants.</b> Individuals with pathogenic variants in <i>ERCC2</i> exhibit significant <a class="def" href="/books/n/gene/glossary/def-item/allelic-heterogeneity/">allelic heterogeneity</a>. Missense variants with resulting change in amino acids with some residual activity [<a class="bk_pop" href="#xp.REF.lehmann.2001.15">Lehmann 2001</a>] are frequently found in cells from individuals with XP-D [<a class="bk_pop" href="#xp.REF.fassihi.2016.e1236">Fassihi et al 2016</a>]. The p.Arg683Trp <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is common in the Iraqi Jewish population [<a class="bk_pop" href="#xp.REF.falikzaccai.2012.505">Falik-Zaccai et al 2012</a>] and occurs at a <a class="def" href="/books/n/gene/glossary/def-item/hot-spot/">hot spot</a>. The p.Arg683Gln pathogenic variant has been reported in individuals with XP in many parts of the world [<a class="bk_pop" href="#xp.REF.taylor.1997.8658">Taylor et al 1997</a>, <a class="bk_pop" href="#xp.REF.boyle.2008.1194">Boyle et al 2008</a>] (see also <a href="http://www.nature.com/ejhg/journal/v22/n7/full/ejhg2013233a.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Clinical Utility Gene Card</a>).</p><p>Individuals with pathogenic variants in <i>ERCC2</i> may have an XP, TTD, or XP/TTD <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#xp.REF.zhou.2013.831">Zhou et al 2013</a>].</p><p>A mild <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> was reported in Israel [<a class="bk_pop" href="#xp.REF.falikzaccai.2012.505">Falik-Zaccai et al 2012</a>].</p><div id="xp.T.ercc2_variants_discussed_in_this_ge" class="table"><h3><span class="label">Table 7. </span></h3><div class="caption"><p><i>ERCC2</i> Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1397/table/xp.T.ercc2_variants_discussed_in_this_ge/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__xp.T.ercc2_variants_discussed_in_this_ge_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_xp.T.ercc2_variants_discussed_in_this_ge_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_xp.T.ercc2_variants_discussed_in_this_ge_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_xp.T.ercc2_variants_discussed_in_this_ge_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_xp.T.ercc2_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2047C&#x0003e;T</td><td headers="hd_h_xp.T.ercc2_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg683Trp</td><td headers="hd_h_xp.T.ercc2_variants_discussed_in_this_ge_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_000400.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000400<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/protein/NP_000391.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000391<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_xp.T.ercc2_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2048G&#x0003e;A</td><td headers="hd_h_xp.T.ercc2_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg683Gln</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>ERCC2</i> codes for an 86.9-kd protein of 760 amino acids. ERCC2, like the ERCC3 (XPB) protein, is also a DNA helicase (but unwinds DNA in the 5'- 3' direction). ERCC2 is part of basal <a class="def" href="/books/n/gene/glossary/def-item/transcription-factor/">transcription factor</a> TFIIH that is involved in regulation of the basal rate of transcription (RNA synthesis) of active genes, as well as in NER.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> XP results from absent or<a href="/books/NBK1397/#xp.molgen.TA"> inactivated TFIIH basal transcription factor complex helicase XPD subunit</a>. Abnormal ERCC2 in persons with XP results in persistent NER protein accumulation at sites of DNA damage while abnormal ERCC2 in persons with TTD results in failure of accumulation of NER proteins at sites of localized DNA damage [<a class="bk_pop" href="#xp.REF.boyle.2008.1194">Boyle et al 2008</a>]. See also <a class="figpopup" href="/books/NBK1397/table/xp.T.phenotype_correlations_by_gene_in_x/?report=objectonly" target="object" rid-figpopup="figxpTphenotypecorrelationsbygeneinx" rid-ob="figobxpTphenotypecorrelationsbygeneinx">Table 2</a>.</p></div><div id="xp.ERCC3_XPB"><h4><i>ERCC3</i> (<i>XPB</i>)</h4><p><b>Gene structure.</b>
<i>ERCC3</i> codes for a 2.75-kb <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a>. It comprises 15 exons and 14 introns (<a href="/nuccore/NM_000122.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000122.1</a>).</p><p><b>Pathogenic variants.</b> Nonsense, frameshift, and <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> defects have been reported [<a class="bk_pop" href="#xp.REF.oh.2006.1092">Oh et al 2006</a>, <a class="bk_pop" href="#xp.REF.fassihi.2016.e1236">Fassihi et al 2016</a>] (see also <a href="http://www.nature.com/ejhg/journal/v22/n7/full/ejhg2013233a.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Clinical Utility Gene Card</a>).</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>ERCC3</i> codes for an 89.3-kd protein of 782 amino acids that functions as a 3'- 5' DNA helicase in unwinding DNA. The <i>ERCC3</i>-encoded protein is part of the TFIIH complex, which is involved in regulation of the basal rate of transcription (RNA synthesis) of active genes, as well as in nucleotide excision repair.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> XP results from absent or inactivated <a href="/books/NBK1397/#xp.molgen.TA">TFIIH basal transcription factor complex helicase XPB subunit</a> protein. Affected individuals have severe disease with neurologic involvement or mild disease without neurologic involvement [<a class="bk_pop" href="#xp.REF.oh.2007.1359">Oh et al 2007</a>, <a class="bk_pop" href="#xp.REF.fassihi.2016.e1236">Fassihi et al 2016</a>]. See also <a class="figpopup" href="/books/NBK1397/table/xp.T.phenotype_correlations_by_gene_in_x/?report=objectonly" target="object" rid-figpopup="figxpTphenotypecorrelationsbygeneinx" rid-ob="figobxpTphenotypecorrelationsbygeneinx">Table 2</a>.</p></div><div id="xp.ERCC4_XPF"><h4><i>ERCC4</i> (<i>XPF</i>)</h4><p><b>Gene structure.</b>
<i>ERCC4</i> codes for a 6.7-kb <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a>. It comprises 11 exons and ten introns (<a href="/nuccore/NM_005236.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_005236.2</a>).</p><p><b>Pathogenic variants.</b> Missense variants have been reported [<a class="bk_pop" href="#xp.REF.fassihi.2016.e1236">Fassihi et al 2016</a>] (see also <a href="http://www.nature.com/ejhg/journal/v22/n7/full/ejhg2013233a.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Clinical Utility Gene Card</a>).</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>ERCC4</i> codes for a 103.3-kd protein of 905 amino acids that serves as a DNA endonuclease 5' to the lesion.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> XP results from absent or inactivated <a href="/books/NBK1397/#xp.molgen.TA">DNA repair endonuclease XPF</a>. Loss of XPF may result in mild disease or adult onset of severe neurologic degeneration [Author, personal observation], or features of FA, CS, XP/CS complex, and XP/CS/FA. See also <a class="figpopup" href="/books/NBK1397/table/xp.T.phenotype_correlations_by_gene_in_x/?report=objectonly" target="object" rid-figpopup="figxpTphenotypecorrelationsbygeneinx" rid-ob="figobxpTphenotypecorrelationsbygeneinx">Table 2</a> [<a class="bk_pop" href="#xp.REF.bogliolo.2013.800">Bogliolo et al 2013</a>, <a class="bk_pop" href="#xp.REF.kashiyama.2013.807">Kashiyama et al 2013</a>, <a class="bk_pop" href="#xp.REF.fassihi.2016.e1236">Fassihi et al 2016</a>].</p></div><div id="xp.ERCC5_XPG"><h4><i>ERCC5</i> (<i>XPG</i>)</h4><p><b>Gene structure.</b>
<i>ERCC5</i> codes for a 4.1-kb <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> (<a href="/nuccore/NM_000123.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000123.3</a>). It comprises 15 exons and 14 introns [<a class="bk_pop" href="#xp.REF.emmert.2001.1443">Emmert et al 2001</a>].</p><p><b>Pathogenic variants.</b> Missense, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, frameshift, and <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> variants have been reported [<a class="bk_pop" href="#xp.REF.fassihi.2016.e1236">Fassihi et al 2016</a>] (see also <a href="http://www.nature.com/ejhg/journal/v22/n7/full/ejhg2013233a.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Clinical Utility Gene Card</a>).</p><p>One individual with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>ERCC5</i> (<i>XPG</i>) and minimal neurologic involvement developed retinal atrophy and basal ganglia calcification of the XP/CS complex while being followed at the NIH [<a class="bk_pop" href="#xp.REF.brooks.2013.1324">Brooks et al 2013</a>].</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>ERCC5</i> codes for a protein of 112 kd that functions as a DNA endonuclease 3' to the lesion.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> XP results from absent or inactivated <a href="/books/NBK1397/#xp.molgen.TA">DNA repair protein complementing XP-G cells</a>. Pathogenic variants resulting in markedly truncated ERCC5 are found in individuals with XP-G with the XP/CS complex, while individuals with XP-G without neurologic disease have <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants that retain some activity [<a class="bk_pop" href="#xp.REF.emmert.2002.972">Emmert et al 2002</a>, <a class="bk_pop" href="#xp.REF.moriwaki.2012.304">Moriwaki et al 2012</a>, <a class="bk_pop" href="#xp.REF.fassihi.2016.e1236">Fassihi et al 2016</a>].</p></div><div id="xp.POLH_XPV"><h4><i>POLH</i> (<i>XP-V</i>)</h4><p><b>Gene structure.</b>
<i>POLH</i> codes for a 8.4-kb <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> (<a href="/nuccore/NM_006502.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_006502.2</a>). It comprises 11 exons and ten introns.</p><p><b>Pathogenic variants.</b> Missense, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and frameshift variants have been described [<a class="bk_pop" href="#xp.REF.fassihi.2016.e1236">Fassihi et al 2016</a>] (see also <a href="http://www.nature.com/ejhg/journal/v22/n7/full/ejhg2013233a.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Clinical Utility Gene Card</a>).</p><p>Affected Japanese individuals were described by <a class="bk_pop" href="#xp.REF.tanioka.2007.1745">Tanioka et al [2007]</a>. Affected individuals from different countries who had multiple skin cancers but no neurologic involvement were identified with pathogenic variants in <i>POLH</i> [<a class="bk_pop" href="#xp.REF.inui.2008.2055">Inui et al 2008</a>]. See also <a class="figpopup" href="/books/NBK1397/table/xp.T.phenotype_correlations_by_gene_in_x/?report=objectonly" target="object" rid-figpopup="figxpTphenotypecorrelationsbygeneinx" rid-ob="figobxpTphenotypecorrelationsbygeneinx">Table 2</a>.</p><div id="xp.T.polh_variants_discussed_in_this_gen" class="table"><h3><span class="label">Table 8. </span></h3><div class="caption"><p><i>POLH</i> Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1397/table/xp.T.polh_variants_discussed_in_this_gen/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__xp.T.polh_variants_discussed_in_this_gen_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_xp.T.polh_variants_discussed_in_this_gen_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_xp.T.polh_variants_discussed_in_this_gen_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_xp.T.polh_variants_discussed_in_this_gen_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_xp.T.polh_variants_discussed_in_this_gen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.490G&#x0003e;T&#x000a0;<sup>1</sup></td><td headers="hd_h_xp.T.polh_variants_discussed_in_this_gen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_xp.T.polh_variants_discussed_in_this_gen_1_1_1_3" rowspan="6" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_006502.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_006502<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="/protein/NP_006493.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_006493<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_xp.T.polh_variants_discussed_in_this_gen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.725C&#x0003e;G</td><td headers="hd_h_xp.T.polh_variants_discussed_in_this_gen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ser242Ter</td></tr><tr><td headers="hd_h_xp.T.polh_variants_discussed_in_this_gen_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.764+1G&#x0003e;A</td><td headers="hd_h_xp.T.polh_variants_discussed_in_this_gen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_xp.T.polh_variants_discussed_in_this_gen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.916G&#x0003e;T</td><td headers="hd_h_xp.T.polh_variants_discussed_in_this_gen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu306Ter</td></tr><tr><td headers="hd_h_xp.T.polh_variants_discussed_in_this_gen_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1661delA</td><td headers="hd_h_xp.T.polh_variants_discussed_in_this_gen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_xp.T.polh_variants_discussed_in_this_gen_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Del <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 10</td><td headers="hd_h_xp.T.polh_variants_discussed_in_this_gen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="xp.TF.8.1"><p class="no_margin">Results in abnormal <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> [<a class="bk_pop" href="#xp.REF.masaki.2008.144">Masaki et al 2008</a>]</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>POLH</i> (polymerase eta) codes for a 78.4-kd protein of 713 amino acids that functions as an error-prone polymerase [<a class="bk_pop" href="#xp.REF.broughton.2002.815">Broughton et al 2002</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> XP results from absent or inactivated DNA polymerase eta.</p></div><div id="xp.XPA"><h4><i>XPA</i></h4><p><b>Gene structure.</b>
<i>XPA</i> codes for a 1.4-kb <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a>. It comprises six exons and five introns (<a href="/nuccore/NM_000380.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000380.3</a>).</p><p><b>Pathogenic variants.</b> A pathogenic founder <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> creating a <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> variant in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 3 of <i>XPA</i>, c.390-1G&#x0003e;C, is estimated to occur at a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> frequency of approximately 1% of the Japanese population. Individuals who are <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for this allele have severe, progressive neurologic degeneration; carriers are clinically normal [<a class="bk_pop" href="#xp.REF.nishigori.1994.191">Nishigori et al 1994</a>, <a class="bk_pop" href="#xp.REF.hirai.2006.171">Hirai et al 2006</a>]. This <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a> appeared in the Japanese population approximately 120 generations (~2400 years) ago [<a class="bk_pop" href="#xp.REF.imoto.2013.175">Imoto et al 2013</a>]. Persons of Japanese heritage who are compound heterozygotes for this <i>XPA</i> variant and a second <i>XPA</i> variant have milder disease than those who are homozygous for the founder variant [<a class="bk_pop" href="#xp.REF.takahashi.2010.2481">Takahashi et al 2010</a>] (see also <a href="http://www.nature.com/ejhg/journal/v22/n7/full/ejhg2013233a.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Clinical Utility Gene Card</a>).</p><p>A <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variant, p.Arg228Ter, is common in the Tunisian population and results in mild disease [<a class="bk_pop" href="#xp.REF.messaoud.2010.883">Messaoud et al 2010</a>].</p><p>Although other common pathogenic alleles have been described in population isolates, most pathogenic alleles are <a class="def" href="/books/n/gene/glossary/def-item/private/">private</a>. Nonsense variants have been reported in both alleles in cells from individuals in complementation group XP-A.</p><p>Mild clinical features were found in an individual with an <i>XPA</i> <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> variant resulting in 5% of normal residual <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> [<a class="bk_pop" href="#xp.REF.sidwell.2006.81">Sidwell et al 2006</a>]. Variants near the C-terminal <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a> of <i>XPA</i> had milder neurologic and cutaneous symptoms and greater residual DNA repair activity in several Japanese persons with XP [<a class="bk_pop" href="#xp.REF.takahashi.2010.2481">Takahashi et al 2010</a>].</p><div id="xp.T.xpa_variants_discussed_in_this_gene" class="table"><h3><span class="label">Table 9. </span></h3><div class="caption"><p><i>XPA</i> Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1397/table/xp.T.xpa_variants_discussed_in_this_gene/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__xp.T.xpa_variants_discussed_in_this_gene_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_xp.T.xpa_variants_discussed_in_this_gene_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_xp.T.xpa_variants_discussed_in_this_gene_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_xp.T.xpa_variants_discussed_in_this_gene_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_xp.T.xpa_variants_discussed_in_this_gene_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.335_338delTTATinsCATAAGAAA</td><td headers="hd_h_xp.T.xpa_variants_discussed_in_this_gene_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Phe112SerfsTer2</td><td headers="hd_h_xp.T.xpa_variants_discussed_in_this_gene_1_1_1_3" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_000380.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000380<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/protein/NP_000371.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000371<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_xp.T.xpa_variants_discussed_in_this_gene_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.390-1G&#x0003e;C</td><td headers="hd_h_xp.T.xpa_variants_discussed_in_this_gene_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_xp.T.xpa_variants_discussed_in_this_gene_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.682C&#x0003e;T</td><td headers="hd_h_xp.T.xpa_variants_discussed_in_this_gene_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg228Ter</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>XPA</i> codes for an <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> corresponding to a 31.3-kd protein of 273 amino acids that functions in maintaining single-stranded regions during repair.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> XP results from absent or inactivated <a href="/books/NBK1397/#xp.molgen.TA">XPA protein</a>.</p></div><div id="xp.XPC"><h4><i>XPC</i></h4><p><b>Gene structure.</b>
<i>XPC</i> codes for a 3.5-kb <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> (<a href="/nuccore/NM_004628.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_004628.4</a>). It comprises 16 exons [<a class="bk_pop" href="#xp.REF.khan.2002.3624">Khan et al 2002</a>].</p><p><b>Pathogenic variants.</b> Nonsense, <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a>, and frameshift variants have been reported in both alleles in cells from individuals in complementation group XP-C. Pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants are less frequent [<a class="bk_pop" href="#xp.REF.khan.2006.84">Khan et al 2006</a>, <a class="bk_pop" href="#xp.REF.fassihi.2016.e1236">Fassihi et al 2016</a>] (see also <a href="http://www.nature.com/ejhg/journal/v22/n7/full/ejhg2013233a.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Clinical Utility Gene Card</a>).</p><p>p.Val548AlafsTer25, a <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a> in <i>XPC</i> resulting in severe disease, was reported in persons with XP from North Africa (Algeria, Morocco, and Tunisia) [<a class="bk_pop" href="#xp.REF.mahindra.2008.881">Mahindra et al 2008</a>, <a class="bk_pop" href="#xp.REF.ben_rekaya.2009.426">Ben Rekaya et al 2009</a>, <a class="bk_pop" href="#xp.REF.soufir.2010.1537">Soufir et al 2010</a>, <a class="bk_pop" href="#xp.REF.tamura.2010a.1491">Tamura et al 2010a</a>]. Haplotype analysis suggested that this variant arose about 50 generations (1250 years) ago [<a class="bk_pop" href="#xp.REF.soufir.2010.1537">Soufir et al 2010</a>]. The frequency of the African <i>XPC</i> founder variant is not known.</p><div id="xp.T.xpc_variants_discussed_in_this_gene" class="table"><h3><span class="label">Table 10. </span></h3><div class="caption"><p><i>XPC</i> Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1397/table/xp.T.xpc_variants_discussed_in_this_gene/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__xp.T.xpc_variants_discussed_in_this_gene_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_xp.T.xpc_variants_discussed_in_this_gene_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_xp.T.xpc_variants_discussed_in_this_gene_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_xp.T.xpc_variants_discussed_in_this_gene_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_xp.T.xpc_variants_discussed_in_this_gene_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1643_1644delTG</td><td headers="hd_h_xp.T.xpc_variants_discussed_in_this_gene_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Val548AlafsTer25</td><td headers="hd_h_xp.T.xpc_variants_discussed_in_this_gene_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_004628.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_004628<wbr style="display:inline-block"></wbr>​.4</a><br /><a href="/protein/NP_004619.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_004619<wbr style="display:inline-block"></wbr>​.3</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>XPC</i> codes for a 105.9-kd protein of 940 amino acids. The XPC protein is involved with recognition of DNA damage and global genome repair.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> XP results from absent or inactivated <a href="/books/NBK1397/#xp.molgen.TA">XPC protein</a>. Individuals with <i>XPC</i> splice lariat variants may have severe or mild disease [<a class="bk_pop" href="#xp.REF.khan.2004.343">Khan et al 2004</a>, <a class="bk_pop" href="#xp.REF.khan.2009.114">Khan et al 2009</a>]: those with mild disease have about 3% of normal residual <i>XPC</i> <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> while those with severe disease have no detectible <i>XPC</i> mRNA. Persons with pathogenic variants in <i>XPC</i> typically do not have acute burning on minimal sun exposure [<a class="bk_pop" href="#xp.REF.khan.2009.114">Khan et al 2009</a>]. See also <a class="figpopup" href="/books/NBK1397/table/xp.T.phenotype_correlations_by_gene_in_x/?report=objectonly" target="object" rid-figpopup="figxpTphenotypecorrelationsbygeneinx" rid-ob="figobxpTphenotypecorrelationsbygeneinx">Table 2</a>.</p></div></div></div><div id="xp.References"><h2 id="_xp_References_">References</h2><div id="xp.Published_Guidelines__Consensus_State"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="xp.REF.tamura.2010">Tamura D, DiGiovanna JJ, Kraemer KH. Xeroderma pigmentosum. In: Lebwohl MG, Heymann WR, Berth-Jones J, Coulson I, eds. <em>Treatment of Skin Disease.</em> 3 ed. London, UK: Elsevier; 2010:789-92.</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.tamura.2014">Tamura D, Kraemer KH, DiGiovanna JJ. Xeroderma pigmentosum. In: Lebwohl MG, Heymann WR, Berth-Jones J, Coulson I, eds. <em>Treatment of Skin Disease: Comprehensive Therapeutic Strategies</em>. 4 ed. London, UK: Elsevier; 2014.</div></li></ul></div><div id="xp.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="xp.REF.ahmad.2010.e1000871">Ahmad A, Enzlin JH, Bhagwat NR, Wijgers N, Raams A, Appledoorn E, Theil AF. J Hoeijmakers JH, Vermeulen W, J Jaspers NG, Sch&#x000e4;rer OD, Niedernhofer LJ. Mislocalization of XPF-ERCC1 nuclease contributes to reduced DNA repair in XP-F patients. <span><span class="ref-journal">PLoS Genet. </span>2010;<span class="ref-vol">6</span>:e1000871.</span> [<a href="/pmc/articles/PMC2832669/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2832669</span></a>] [<a href="/pubmed/20221251" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20221251</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.ali.2009.442">Ali JT, Mukasa Y, Coulson IH. Xeroderma pigmentosum: early diagnostic features and an adverse consequence of photoprotection. <span><span class="ref-journal">Clin Exp Dermatol. </span>2009;<span class="ref-vol">34</span>:442–3.</span> [<a href="/pubmed/19309384" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19309384</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.arlett.2006.510">Arlett CF, Plowman PN, Rogers PB, Parris CN, Abbaszadeh F, Green MH, McMillan TJ, Bush C, Foray N, Lehmann AR. Clinical and cellular ionizing radiation sensitivity in a patient with xeroderma pigmentosum. <span><span class="ref-journal">Br J Radiol. </span>2006;<span class="ref-vol">79</span>:510–7.</span> [<a href="/pubmed/16714754" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16714754</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.ben_rekaya.2014">Ben Rekaya M, Laroussi N, Messaoud O, Jones M, Jerbi M, Naouali C, Bouyacoub Y, Chargui M, Kefi R, Fazaa B, Boubaker MS, Boussen H, Mokni M, Abdelhak S, Zghal M, Khaled A, Yacoub-Youssef H. A founder large deletion mutation in Xeroderma pigmentosum-Variant form in Tunisia: implication for molecular diagnosis and therapy. Biomed Res Int. 2014;2014:256245. [<a href="/pmc/articles/PMC4024419/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4024419</span></a>] [<a href="/pubmed/24877075" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24877075</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.ben_rekaya.2009.426">Ben Rekaya M, Messaoud O, Talmoudi F, Nouira S, Ouragini H, Amouri A, Boussen H, Boubaker S, Mokni M, Mokthar I, Abdelhak S, Zghal M. High frequency of the V548A fs X572 XPC mutation in Tunisia: implication for molecular diagnosis. <span><span class="ref-journal">J Hum Genet. </span>2009;<span class="ref-vol">54</span>:426–9.</span> [<a href="/pubmed/19478817" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19478817</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.berneburg.2007">Berneburg M, Kraemer KH. Xeroderma pigmentosum and other DNA repair-deficient photodermatoses. In: Lim H, H&#x000f6;nigsmann H, Hawk JLM, eds. <em>Photodermatology</em>. New York, NY: Informa Healthcare; 2007:239-50.</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.bogliolo.2013.800">Bogliolo M, Schuster B, Stoepker C, Derkunt B, Su Y, Raams A, Trujillo JP, Minguill&#x000f3;n J, Ram&#x000ed;rez MJ, Pujol R, Casado JA, Ba&#x000f1;os R, Rio P, Knies K, Z&#x000fa;&#x000f1;iga S, Ben&#x000ed;tez J, Bueren JA, Jaspers NG, Sch&#x000e4;rer OD, de Winter JP, Schindler D, Surrall&#x000e9;s J. Mutations in ERCC4, encoding the DNA-repair endonuclease XPF, cause Fanconi anemia. <span><span class="ref-journal">Am J Hum Genet. </span>2013;<span class="ref-vol">92</span>:800–6.</span> [<a href="/pmc/articles/PMC3644630/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3644630</span></a>] [<a href="/pubmed/23623386" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23623386</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.bootsma.2002">Bootsma D, Kraemer KH, Cleaver JE, Hoeijmakers JHJ. Nucleotide excision repair syndromes: xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy. In: Vogelstein B, Kinzler KW, eds. <em>The Genetic Basis of Human Cancer</em>. 2 ed. New York, NY: McGraw-Hill; 2002:211-37.</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.boyle.2008.1194">Boyle J, Ueda T, Oh KS, Imoto K, Tamura D, Jagdeo J, Khan SG, Nadem C, Digiovanna JJ, Kraemer KH. Persistence of repair proteins at unrepaired DNA damage distinguishes diseases with ERCC2 (XPD) mutations: cancer-prone xeroderma pigmentosum vs. non-cancer-prone trichothiodystrophy. <span><span class="ref-journal">Hum Mutat. </span>2008;<span class="ref-vol">29</span>:1194–208.</span> [<a href="/pmc/articles/PMC3477783/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3477783</span></a>] [<a href="/pubmed/18470933" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18470933</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.bradford.2011.168">Bradford PT, Goldstein AM, Tamura D, Khan SG, Ueda T, Boyle J, Oh KS, Imoto K, Inui H, Moriwaki S, Emmert S, Pike KM, Raziuddin A, Plona TM, DiGiovanna JJ, Tucker MA, Kraemer KH. Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of DNA repair. <span><span class="ref-journal">J Med Genet. </span>2011;<span class="ref-vol">48</span>:168–76.</span> [<a href="/pmc/articles/PMC3235003/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3235003</span></a>] [<a href="/pubmed/21097776" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21097776</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.brooks.2013.1324">Brooks BP, Thompson AH, Bishop RJ, Clayton JA, Chan CC, Tsilou ET, Zein WM, Tamura D, Khan SG, Ueda T, Boyle J, Oh KS, Imoto K, Inui H, Moriwaki S, Emmert S, Iliff NT, Bradford P, Digiovanna JJ, Kraemer KH. Ocular manifestations of xeroderma pigmentosum: long-term follow-up highlights the role of DNA repair in protection from sun damage. <span><span class="ref-journal">Ophthalmology. </span>2013;<span class="ref-vol">120</span>:1324–36.</span> [<a href="/pmc/articles/PMC3702678/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3702678</span></a>] [<a href="/pubmed/23601806" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23601806</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.broughton.2001.2539">Broughton BC, Berneburg M, Fawcett H, Taylor EM, Arlett CF, Nardo T, Stefanini M, Menefee E, Price VH, Queille S, Sarasin A, Bohnert E, Krutmann J, Davidson R, Kraemer KH, Lehmann AR. Two individuals with features of both xeroderma pigmentosum and trichothiodystrophy highlight the complexity of the clinical outcomes of mutations in the XPD gene. <span><span class="ref-journal">Hum Mol Genet. </span>2001;<span class="ref-vol">10</span>:2539–47.</span> [<a href="/pubmed/11709541" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11709541</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.broughton.2002.815">Broughton BC, Cordonnier A, Kleijer WJ, Jaspers NG, Fawcett H, Raams A, Garritsen VH, Stary A, Avril MF, Boudsocq F, Masutani C, Hanaoka F, Fuchs RP, Sarasin A, Lehmann AR. Molecular analysis of mutations in DNA polymerase eta in xeroderma pigmentosum-variant patients. <span><span class="ref-journal">Proc Natl Acad Sci USA. </span>2002;<span class="ref-vol">99</span>:815–20.</span> [<a href="/pmc/articles/PMC117388/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC117388</span></a>] [<a href="/pubmed/11773631" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11773631</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.butt.2010.534">Butt FM, Moshi JR, Owibingire S, Chindia ML. Xeroderma pigmentosum: a review and case series. <span><span class="ref-journal">J Craniomaxillofac Surg. </span>2010;<span class="ref-vol">38</span>:534–7.</span> [<a href="/pubmed/20346687" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20346687</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.calmels.2016.26">Calmels N, Greff G, Obringer C, Kempf N, Gasnier C, Tarabeux J, Miguet M, Baujat G, Bessis D, Bretones P, Cavau A, Digeon B, Doco-Fenzy M, Doray B, Feillet F, Gardeazabal J, Gener B, Julia S, Llano-Rivas I, Mazur A, Michot C, Renaldo-Robin F, Rossi M, Sabouraud P, Keren B, Depienne C, Muller J, Mandel JL, Laugel V. Uncommon nucleotide excision repair phenotypes revealed by targeted high-throughput sequencing. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2016;<span class="ref-vol">11</span>:26.</span> [<a href="/pmc/articles/PMC4804614/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4804614</span></a>] [<a href="/pubmed/27004399" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27004399</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.chavanne.2000.1974">Chavanne F, Broughton BC, Pietra D, Nardo T, Browitt A, Lehmann AR, Stefanini M. Mutations in the XPC gene in families with xeroderma pigmentosum and consequences at the cell, protein, and transcript levels. <span><span class="ref-journal">Cancer Res. </span>2000;<span class="ref-vol">60</span>:1974–82.</span> [<a href="/pubmed/10766188" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10766188</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.christenzaech.2009.1285">Christen-Zaech S, Imoto K, Khan SG, Oh KS, Tamura D, Digiovanna JJ, Boyle J, Patronas NJ, Schiffmann R, Kraemer KH, Paller AS. Unexpected occurrence of xeroderma pigmentosum in an uncle and nephew. <span><span class="ref-journal">Arch Dermatol. </span>2009;<span class="ref-vol">145</span>:1285–91.</span> [<a href="/pmc/articles/PMC3472955/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3472955</span></a>] [<a href="/pubmed/19917958" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19917958</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.cleaver.1999.9">Cleaver JE, Thompson LH, Richardson AS, States JC. A summary of mutations in the UV-sensitive disorders: xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy. <span><span class="ref-journal">Hum Mutat. </span>1999;<span class="ref-vol">14</span>:9–22.</span> [<a href="/pubmed/10447254" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10447254</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.clement.2010.21">Clement FC, Camenisch U, Fei J, Kaczmarek N, Mathieu N, Naegeli H. Dynamic two-stage mechanism of versatile DNA damage recognition by xeroderma pigmentosum group C protein. <span><span class="ref-journal">Mutat Res. </span>2010;<span class="ref-vol">685</span>:21–8.</span> [<a href="/pubmed/19686765" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19686765</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.correa.2015.m85">Correa R, Salpea P, Stratakis CA. Carney complex: an update. <span><span class="ref-journal">Eur J Endocrinol. </span>2015;<span class="ref-vol">173</span>:M85–97.</span> [<a href="/pmc/articles/PMC4553126/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4553126</span></a>] [<a href="/pubmed/26130139" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26130139</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.digiovanna.2012.785">DiGiovanna JJ, Kraemer KH. Shining a light on xeroderma pigmentosum. <span><span class="ref-journal">J Invest Dermatol. </span>2012;<span class="ref-vol">132</span>:785–96.</span> [<a href="/pmc/articles/PMC3279615/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3279615</span></a>] [<a href="/pubmed/22217736" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22217736</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.digiovanna.1998.153">DiGiovanna JJ, Patronas N, Katz D, Abangan D, Kraemer KH. Xeroderma pigmentosum: spinal cord astrocytoma with 9-year survival after radiation and isotretinoin therapy. <span><span class="ref-journal">J Cutan Med Surg. </span>1998;<span class="ref-vol">2</span>:153–8.</span> [<a href="/pubmed/9479081" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9479081</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.dollfus.2003.107">Dollfus H, Porto F, Caussade P, Speeg-Schatz C, Sahel J, Grosshans E, Flament J, Sarasin A. Ocular manifestations in the inherited DNA repair disorders. <span><span class="ref-journal">Surv Ophthalmol. </span>2003;<span class="ref-vol">48</span>:107–22.</span> [<a href="/pubmed/12559331" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12559331</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.emmert.2001.1443">Emmert S, Schneider TD, Khan SG, Kraemer KH. The human XPG gene: gene architecture, alternative splicing and single nucleotide polymorphisms. <span><span class="ref-journal">Nucleic Acids Res. </span>2001;<span class="ref-vol">29</span>:1443–52.</span> [<a href="/pmc/articles/PMC31292/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC31292</span></a>] [<a href="/pubmed/11266544" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11266544</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.emmert.2002.972">Emmert S, Slor H, Busch DB, Batko S, Albert RB, Coleman D, Khan SG, Abu-Libdeh B, DiGiovanna JJ, Cunningham BB, Lee MM, Crollick J, Inui H, Ueda T, Hedayati M, Grossman L, Shahlavi T, Cleaver JE, Kraemer KH. Relationship of neurologic degeneration to genotype in three xeroderma pigmentosum group G patients. <span><span class="ref-journal">J Invest Dermatol. </span>2002;<span class="ref-vol">118</span>:972–82.</span> [<a href="/pubmed/12060391" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12060391</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.faghri.2008.609">Faghri S, Tamura D, Kraemer KH, Digiovanna JJ. Trichothiodystrophy: a systematic review of 112 published cases characterises a wide spectrum of clinical manifestations. <span><span class="ref-journal">J Med Genet. </span>2008;<span class="ref-vol">45</span>:609–21.</span> [<a href="/pmc/articles/PMC3459585/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3459585</span></a>] [<a href="/pubmed/18603627" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18603627</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.falikzaccai.2012.505">Falik-Zaccai TC, Erel-Segal R, Horev L, Bitterman-Deutsch O, Koka S, Chaim S, Keren Z, Kalfon L, Gross B, Segal Z, Orgal S, Shoval Y, Slor H, Spivak G, Hanawalt PC. A novel XPD mutation in a compound heterozygote; the mutation in the second allele is present in three homozygous patients with mild sun sensitivity. <span><span class="ref-journal">Environ.Mol.Mutagen. </span>2012;<span class="ref-vol">53</span>:505–14.</span> [<a href="/pubmed/22826098" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22826098</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.fassihi.2016.e1236">Fassihi H, Sethi M, Fawcett H, Wing J, Chandler N, Mohammed S, Craythorne E, Morley AM, Lim R, Turner S, Henshaw T, Garrood I, Giunti P, Hedderly T, Abiona A, Naik H, Harrop G, McGibbon D, Jaspers NG, Botta E, Nardo T, Stefanini M, Young AR, Sarkany RP, Lehmann AR. Deep phenotyping of 89 xeroderma pigmentosum patients reveals unexpected heterogeneity dependent on the precise molecular defect. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2016;<span class="ref-vol">113</span>:E1236–45.</span> [<a href="/pmc/articles/PMC4780618/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4780618</span></a>] [<a href="/pubmed/26884178" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26884178</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.giannotti.2003.33">Giannotti B, Vanzi L, Difonzo EM, Pimpinelli N. The treatment of basal cell carcinomas in a patient with xeroderma pigmentosum with a combination of imiquimod 5% cream and oral acitretin. <span><span class="ref-journal">Clin Exp Dermatol. </span>2003;<span class="ref-vol">28</span> Suppl 1:33–5.</span> [<a href="/pubmed/14616811" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14616811</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.gigliamari.2004.714">Giglia-Mari G, Coin F, Ranish JA, Hoogstraten D, Theil A, Wijgers N, Jaspers NG, Raams A, Argentini M, Van der Spek PJ, Botta E, Stefanini M, Egly JM, Aebersold R, Hoeijmakers JH, Vermeulen W. A new, tenth subunit of TFIIH is responsible for the DNA repair syndrome trichothiodystrophy group A. <span><span class="ref-journal">Nat Genet. </span>2004;<span class="ref-vol">36</span>:714–9.</span> [<a href="/pubmed/15220921" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15220921</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.graham.2001.291">Graham JM Jr, Anyane-Yeboa K, Raams A, Appeldoorn E, Kleijer WJ, Garritsen VH, Busch D, Edersheim TG, Jaspers NG. Cerebro-oculo-facio-skeletal syndrome with a nucleotide excision-repair defect and a mutated XPD gene, with prenatal diagnosis in a triplet pregnancy. <span><span class="ref-journal">Am J Hum Genet. </span>2001;<span class="ref-vol">69</span>:291–300.</span> [<a href="/pmc/articles/PMC1235303/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1235303</span></a>] [<a href="/pubmed/11443545" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11443545</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.hadjrabia.2013.1109">Hadj-Rabia S, Oriot D, Soufir N, Dufresne H, Bourrat E, Mallet S, Poulhalon N, Ezzedine K, Grandchamp B, Ta&#x000ef;eb A, Catteau B, Sarasin A, Bodemer C. Unexpected extradermatological findings in 31 patients with xeroderma pigmentosum type C. <span><span class="ref-journal">Br J Dermatol. </span>2013;<span class="ref-vol">168</span>:1109–13.</span> [<a href="/pubmed/23278166" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23278166</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.heller.2015.734">Heller ER, Khan SG, Kuschal C, Tamura D, DiGiovanna JJ, Kraemer KH. Mutations in the TTDN1 gene are associated with a distinct trichothiodystrophy phenotype. <span><span class="ref-journal">J Invest Dermatol. </span>2015;<span class="ref-vol">135</span>:734–41.</span> [<a href="/pmc/articles/PMC4530629/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4530629</span></a>] [<a href="/pubmed/25290684" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25290684</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.hirai.2006.171">Hirai Y, Kodama Y, Moriwaki S, Noda A, Cullings HM, Macphee DG, Kodama K, Mabuchi K, Kraemer KH, Land CE, Nakamura N. Heterozygous individuals bearing a founder mutation in the XPA DNA repair gene comprise nearly 1% of the Japanese population. <span><span class="ref-journal">Mutat Res. </span>2006;<span class="ref-vol">601</span>:171–8.</span> [<a href="/pubmed/16905156" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16905156</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.horibata.2004.15410">Horibata K, Iwamoto Y, Kuraoka I, Jaspers NG, Kurimasa A, Oshimura M, Ichihashi M, Tanaka K. Complete absence of Cockayne syndrome group B gene product gives rise to UV-sensitive syndrome but not Cockayne syndrome. <span><span class="ref-journal">Proc Natl Acad Sci USA. </span>2004;<span class="ref-vol">101</span>:15410–5.</span> [<a href="/pmc/articles/PMC524447/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC524447</span></a>] [<a href="/pubmed/15486090" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15486090</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.imoto.2013.175">Imoto K, Nadem C, Moriwaki S, Nishigori C, Oh KS, Khan SG, Goldstein AM, Kraemer KH. Ancient origin of a Japanese xeroderma pigmentosum founder mutation. <span><span class="ref-journal">J Dermatol Sci. </span>2013;<span class="ref-vol">69</span>:175–6.</span> [<a href="/pmc/articles/PMC3570715/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3570715</span></a>] [<a href="/pubmed/23194742" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23194742</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.inui.2008.2055">Inui H, Oh KS, Nadem C, Ueda T, Khan SG, Metin A, Gozukara E, Emmert S, Slor H, Busch DB, Baker CC, DiGiovanna JJ, Tamura D, Seitz CS, Gratchev A, Wu WH, Chung KY, Chung HJ, Azizi E, Woodgate R, Schneider TD, Kraemer KH. Xeroderma pigmentosum-variant patients from America, Europe, and Asia. <span><span class="ref-journal">J Invest Dermatol. </span>2008;<span class="ref-vol">128</span>:2055–68.</span> [<a href="/pmc/articles/PMC2562952/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2562952</span></a>] [<a href="/pubmed/18368133" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18368133</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.itin.2001.891">Itin PH, Sarasin A, Pittelkow MR. Trichothiodystrophy: update on the sulfur-deficient brittle hair syndromes. <span><span class="ref-journal">J Am Acad Dermatol. </span>2001;<span class="ref-vol">44</span>:891–920.</span> [<a href="/pubmed/11369901" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11369901</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.itoh.1994.233">Itoh T, Ono T, Yamaizumi M. A new UV-sensitive syndrome not belonging to any complementation groups of xeroderma pigmentosum or Cockayne syndrome: siblings showing biochemical characteristics of Cockayne syndrome without typical clinical manifestations. <span><span class="ref-journal">Mutat Res. </span>1994;<span class="ref-vol">314</span>:233–48.</span> [<a href="/pubmed/7513056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7513056</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.jaspers.2007.457">Jaspers NG, Raams A, Silengo MC, Wijgers N, Niedernhofer LJ, Robinson AR, Giglia-Mari G, Hoogstraten D, Kleijer WJ, Hoeijmakers JH, Vermeulen W. First reported patient with human ERCC1 deficiency has cerebro-oculo-facio-skeletal syndrome with a mild defect in nucleotide excision repair and severe developmental failure. <span><span class="ref-journal">Am J Hum Genet. </span>2007;<span class="ref-vol">80</span>:457–66.</span> [<a href="/pmc/articles/PMC1821117/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1821117</span></a>] [<a href="/pubmed/17273966" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17273966</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.jerbi.2016.439">Jerbi M, Ben Rekaya M, Naouali C, Jones M, Messaoud O, Tounsi H, Nagara M, Chargui M, Kefi R, Boussen H, Mokni M, Mrad R, Boubaker MS, Abdelhak S, Khaled A, Zghal M, Yacoub-Youssef H. Clinical, genealogical and molecular investigation of the xeroderma pigmentosum type C complementation group in Tunisia. <span><span class="ref-journal">Br J Dermatol. </span>2016;<span class="ref-vol">174</span>:439–43.</span> [<a href="/pubmed/26211814" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26211814</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.kashiyama.2013.807">Kashiyama K, Nakazawa Y, Pilz DT, Guo C, Shimada M, Sasaki K, Fawcett H, Wing JF, Lewin SO, Carr L, Li TS, Yoshiura K, Utani A, Hirano A, Yamashita S, Greenblatt D, Nardo T, Stefanini M, McGibbon D, Sarkany R, Fassihi H, Takahashi Y, Nagayama Y, Mitsutake N, Lehmann AR, Ogi T. Malfunction of nuclease ERCC1-XPF results in diverse clinical manifestations and causes Cockayne syndrome, xeroderma pigmentosum, and Fanconi anemia. <span><span class="ref-journal">Am J Hum Genet. </span>2013;<span class="ref-vol">92</span>:807–19.</span> [<a href="/pmc/articles/PMC3644632/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3644632</span></a>] [<a href="/pubmed/23623389" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23623389</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.khan.2004.343">Khan SG, Metin A, Gozukara E, Inui H, Shahlavi T, Muniz-Medina V, Baker CC, Ueda T, Aiken JR, Schneider TD, Kraemer KH. Two essential splice lariat branchpoint sequences in one intron in a xeroderma pigmentosum DNA repair gene: mutations result in reduced XPC mRNA levels that correlate with cancer risk. <span><span class="ref-journal">Hum Mol Genet. </span>2004;<span class="ref-vol">13</span>:343–52.</span> [<a href="/pubmed/14662655" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14662655</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.khan.2002.3624">Khan SG, Muniz-Medina V, Shahlavi T, Baker CC, Inui H, Ueda T, Emmert S, Schneider TD, Kraemer KH. The human XPC DNA repair gene: arrangement, splice site information content and influence of a single nucleotide polymorphism in a splice acceptor site on alternative splicing and function. <span><span class="ref-journal">Nucleic Acids Res. </span>2002;<span class="ref-vol">30</span>:3624–31.</span> [<a href="/pmc/articles/PMC134237/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC134237</span></a>] [<a href="/pubmed/12177305" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12177305</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.khan.2009.114">Khan SG, Oh KS, Emmert S, Imoto K, Tamura D, Digiovanna JJ, Shahlavi T, Armstrong N, Baker CC, Neuburg M, Zalewski C, Brewer C, Wiggs E, Schiffmann R, Kraemer KH. XPC initiation codon mutation in xeroderma pigmentosum patients with and without neurological symptoms. <span><span class="ref-journal">DNA Repair (Amst). </span>2009;<span class="ref-vol">8</span>:114–25.</span> [<a href="/pmc/articles/PMC2684809/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2684809</span></a>] [<a href="/pubmed/18955168" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18955168</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.khan.2006.84">Khan SG, Oh KS, Shahlavi T, Ueda T, Busch DB, Inui H, Emmert S, Imoto K, Muniz Medina V, Baker CC, DiGiovanna JJ, Schmidt D, Khadavi A, Metin A, Gozukara E, Slor H, Sarasin A, Kraemer KH. Reduced XPC mRNA levels in clinically normal parents of xeroderma pigmentosum patients. <span><span class="ref-journal">Carcinogenesis. </span>2006;<span class="ref-vol">27</span>:84–94.</span> [<a href="/pubmed/16081512" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16081512</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.kleijer.2008.744">Kleijer WJ, Laugel V, Berneburg M, Nardo T, Fawcett H, Gratchev A, Jaspers NG, Sarasin A, Stefanini M, Lehmann AR. Incidence of DNA repair deficiency disorders in western Europe: Xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy. <span><span class="ref-journal">DNA Repair (Amst). </span>2008;<span class="ref-vol">7</span>:744–50.</span> [<a href="/pubmed/18329345" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18329345</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.kraemer.1988.1633">Kraemer KH, DiGiovanna JJ, Moshell AN, Tarone RE, Peck GL. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. <span><span class="ref-journal">N Engl J Med. </span>1988;<span class="ref-vol">318</span>:1633–7.</span> [<a href="/pubmed/3287161" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3287161</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.kraemer.1994.1018">Kraemer KH, Lee MM, Andrews AD, Lambert WC. The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer. The xeroderma pigmentosum paradigm. <span><span class="ref-journal">Arch Dermatol. </span>1994;<span class="ref-vol">130</span>:1018–21.</span> [<a href="/pubmed/8053698" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8053698</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.kraemer.1987.241">Kraemer KH, Lee MM, Scotto J. Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases. <span><span class="ref-journal">Arch Dermatol. </span>1987;<span class="ref-vol">123</span>:241–50.</span> [<a href="/pubmed/3545087" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3545087</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.kraemer.2007.1388">Kraemer KH, Patronas NJ, Schiffmann R, Brooks BP, Tamura D, DiGiovanna JJ. Xeroderma pigmentosum, trichothiodystrophy and Cockayne syndrome: a complex genotype-phenotype relationship. <span><span class="ref-journal">Neuroscience. </span>2007;<span class="ref-vol">145</span>:1388–96.</span> [<a href="/pmc/articles/PMC2288663/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2288663</span></a>] [<a href="/pubmed/17276014" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17276014</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.kraemer.2012">Kraemer KH, Ruenger T. Genome instability, DNA repair, and cancer. In: Wolff K, Katz S, Goldsmith L, Gilchrist B, Leffell D, Paller A, eds. <em>Fitzpatrick's Dermatology in General Medicine</em>. 8 ed. New York, NY: McGraw-Hill; 2012:1227-39.</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.kraemer.1985.33">Kraemer KH, Slor H. Xeroderma pigmentosum. <span><span class="ref-journal">Clin Dermatol. </span>1985;<span class="ref-vol">3</span>:33–69.</span> [<a href="/pubmed/3833325" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3833325</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.kuschal.2016.627">Kuschal C, Botta E, Orioli D, Digiovanna JJ, Seneca S, Keymolen K, Tamura D, Heller E, Khan SG, Caligiuri G, Lanzafame M, Nardo T, Ricotti R, Peverali FA, Stephens R, Zhao Y, Lehmann AR, Baranello L, Levens D, Kraemer KH, Stefanini M. GTF2E2 mutations destabilize the general transcription factor complex TFIIE in individuals with DNA repair-proficient trichothiodystrophy. <span><span class="ref-journal">Am J Hum Genet. </span>2016;<span class="ref-vol">98</span>:627–42.</span> [<a href="/pmc/articles/PMC4833217/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4833217</span></a>] [<a href="/pubmed/26996949" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26996949</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.lai.2013.4">Lai JP, Liu YC, Alimchandani M, Liu Q, Aung PP, Matsuda K, Lee CC, Tsokos M, Hewitt S, Rushing EJ, Tamura D, Levens DL, DiGiovanna JJ, Fine HA, Patronas N, Khan SG, Kleiner DE, Oberholtzer JC, Quezado MM, Kraemer KH. The influence of DNA repair on neurologic degeneration, cachexia, skin cancer and internal neoplasms: autopsy report of four xeroderma pigmentosum patients (XP-A, XP-C and XP-D). <span><span class="ref-journal">Acta Neuropathol Commun. </span>2013;<span class="ref-vol">1</span>:4.</span> [<a href="/pmc/articles/PMC3776212/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3776212</span></a>] [<a href="/pubmed/24252196" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24252196</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.lehmann.2001.15">Lehmann AR. The xeroderma pigmentosum group D (XPD) gene: one gene, two functions, three diseases. <span><span class="ref-journal">Genes Dev. </span>2001;<span class="ref-vol">15</span>:15–23.</span> [<a href="/pubmed/11156600" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11156600</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.liang.2005.224">Liang C, Kraemer KH, Morris A, Schiffmann R, Price VH, Menefee E, DiGiovanna JJ. Characterization of tiger tail banding and hair shaft abnormalities in trichothiodystrophy. <span><span class="ref-journal">J Am Acad Dermatol. </span>2005;<span class="ref-vol">52</span>:224–32.</span> [<a href="/pubmed/15692466" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15692466</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.mahindra.2008.881">Mahindra P, DiGiovanna JJ, Tamura D, Brahim JS, Hornyak TJ, Stern JB, Lee CC, Khan SG, Brooks BP, Smith JA, Driscoll BP, Montemarano AD, Sugarman K, Kraemer KH. Skin cancers, blindness, and anterior tongue mass in African brothers. <span><span class="ref-journal">J Am Acad Dermatol. </span>2008;<span class="ref-vol">59</span>:881–6.</span> [<a href="/pmc/articles/PMC2717011/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2717011</span></a>] [<a href="/pubmed/19119101" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19119101</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.masaki.2008.144">Masaki T, Ono R., Tanioka M., Funasaka Y., Nagano T., Moriwaki S., Nishigori C. Four types of possible founder mutations are responsible for 87% of Japanese patients with Xeroderma pigmentosum variant type. <span><span class="ref-journal">J Dermatol Sci. </span>2008;<span class="ref-vol">52</span>:144–8.</span> [<a href="/pubmed/18703314" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18703314</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.meira.2000.1221">Meira LB, Graham JM Jr, Greenberg CR, Busch DB, Doughty AT, Ziffer DW, Coleman DM, Savre-Train I, Friedberg EC. Manitoba aboriginal kindred with original cerebro-ocular facial syndrome. <span><span class="ref-journal">Am J Hum Genet. </span>2000;<span class="ref-vol">66</span>:1221–8.</span> [<a href="/pmc/articles/PMC1288189/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1288189</span></a>] [<a href="/pubmed/10739753" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10739753</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.messaoud.2010.883">Messaoud O, Ben Rekaya M, Kefi R, Chebel S, Boughammoura-Bouatay A, Bel Hadj Ali H, Gouider-Khouja N, Zili J, Frih-Ayed M, Mokhtar I, Abdelhak S, Zghal M. Identification of a primarily neurological phenotypic expression of xeroderma pigmentosum complementation group A in a Tunisian family. <span><span class="ref-journal">Br J Dermatol. </span>2010;<span class="ref-vol">162</span>:883–6.</span> [<a href="/pubmed/20199544" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20199544</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.moriwaki.2001.47">Moriwaki S, Kraemer KH. Xeroderma pigmentosum--bridging a gap between clinic and laboratory. <span><span class="ref-journal">Photodermatol Photoimmunol Photomed. </span>2001;<span class="ref-vol">17</span>:47–54.</span> [<a href="/pubmed/11338401" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11338401</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.moriwaki.2012.304">Moriwaki S, Takigawa M, Igarashi N, Nagai Y, Amano H, Ishikawa O, Khan SG, Kraemer KH. Xeroderma pigmentosum complementation group G patient with a novel homozygous missense mutation and no neurological abnormalities. <span><span class="ref-journal">Exp Dermatol. </span>2012;<span class="ref-vol">21</span>:304–7.</span> [<a href="/pmc/articles/PMC3305914/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3305914</span></a>] [<a href="/pubmed/22417308" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22417308</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.moslehi.2010.365">Moslehi R, Signore C, Tamura D, Mills JL, Digiovanna JJ, Tucker MA, Troendle J, Ueda T, Boyle J, Khan SG, Oh KS, Goldstein AM, Kraemer KH. Adverse effects of trichothiodystrophy DNA repair and transcription gene disorder on human fetal development. <span><span class="ref-journal">Clin Genet. </span>2010;<span class="ref-vol">77</span>:365–73.</span> [<a href="/pmc/articles/PMC3463936/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3463936</span></a>] [<a href="/pubmed/20002457" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20002457</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.nagore.2003.858">Nagore E, Sevila A, Sanmartin O, Botella-Estrada R, Requena C, Serra-Guillen C, Sanchez-Pedreno P, Guillen C. Excellent response of basal cell carcinomas and pigmentary changes in xeroderma pigmentosum to imiquimod 5% cream. <span><span class="ref-journal">Br J Dermatol. </span>2003;<span class="ref-vol">149</span>:858–61.</span> [<a href="/pubmed/14616381" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14616381</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.nakazawa.2012.586">Nakazawa Y, Sasaki K, Mitsutake N, Matsuse M, Shimada M, Nardo T, Takahashi Y, Ohyama K, Ito K, Mishima H, Nomura M, Kinoshita A, Ono S, Takenaka K, Masuyama R, Kudo T, Slor H, Utani A, Tateishi S, Yamashita S, Stefanini M, Lehmann AR, Yoshiura K, Ogi T. Mutations in UVSSA cause UV-sensitive syndrome and impair RNA polymerase IIo processing in transcription-coupled nucleotide-excision repair. <span><span class="ref-journal">Nat Genet. </span>2012;<span class="ref-vol">44</span>:586–92.</span> [<a href="/pubmed/22466610" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22466610</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.nardo.2009.6209">Nardo T, Oneda R, Spivak G, Vaz B, Mortier L, Thomas P, Orioli D, Laugel V, Stary A, Hanawalt PC, Sarasin A, Stefanini M. A UV-sensitive syndrome patient with a specific CSA mutation reveals separable roles for CSA in response to UV and oxidative DNA damage. <span><span class="ref-journal">Proc Natl Acad Sci USA. </span>2009;<span class="ref-vol">106</span>:6209–14.</span> [<a href="/pmc/articles/PMC2667150/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2667150</span></a>] [<a href="/pubmed/19329487" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19329487</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.nichols.1996.24317">Nichols AF, Ong P, Linn S. Mutations specific to the xeroderma pigmentosum group E Ddb- phenotype. <span><span class="ref-journal">J Biol Chem. </span>1996;<span class="ref-vol">271</span>:24317–20.</span> [<a href="/pubmed/8798680" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8798680</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.niedernhofer.2006.1038">Niedernhofer LJ, Garinis GA, Raams A, Lalai AS, Robinson AR, Appeldoorn E, Odijk H, Oostendorp R, Ahmad A, van Leeuwen W, Theil AF, Vermeulen W, van der Horst FTJ, Meinecke P, Kleijer WJ, Vijg J, Jaspers NGJ, Hoeijmakers JH. A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis. <span><span class="ref-journal">Nature. </span>2006;<span class="ref-vol">444</span>:1038–43.</span> [<a href="/pubmed/17183314" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17183314</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.nishigori.1994.191">Nishigori C, Moriwaki S, Takebe H, Tanaka T, Imamura S. Gene alterations and clinical characteristics of xeroderma pigmentosum group A patients in Japan. <span><span class="ref-journal">Arch Dermatol. </span>1994;<span class="ref-vol">130</span>:191–7.</span> [<a href="/pubmed/7905727" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7905727</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.oh.2011.785">Oh KS, Emmert S, Tamura D, DiGiovanna JJ, Kraemer KH. Multiple skin cancers in adults with mutations in the XP-E (DDB-2) DNA repair gene. <span><span class="ref-journal">J Invest Dermatol. </span>2011;<span class="ref-vol">131</span>:785–8.</span> [<a href="/pmc/articles/PMC3471370/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3471370</span></a>] [<a href="/pubmed/21107348" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21107348</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.oh.2007.1359">Oh KS, Imoto K, Boyle J, Khan SG, Kraemer KH. Influence of XPB helicase on recruitment and redistribution of nucleotide excision repair proteins at sites of UV-induced DNA damage. <span><span class="ref-journal">DNA Repair (Amst). </span>2007;<span class="ref-vol">6</span>:1359–70.</span> [<a href="/pmc/articles/PMC3471374/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3471374</span></a>] [<a href="/pubmed/17509950" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17509950</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.oh.2006.1092">Oh KS, Khan SG, Jaspers NG, Raams A, Ueda T, Lehmann A, Friedmann PS, Emmert S, Gratchev A, Lachlan K, Lucassan A, Baker CC, Kraemer KH. Phenotypic heterogeneity in the XPB DNA helicase gene (ERCC3): xeroderma pigmentosum without and with Cockayne syndrome. <span><span class="ref-journal">Hum Mutat. </span>2006;<span class="ref-vol">27</span>:1092–103.</span> [<a href="/pubmed/16947863" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16947863</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.ohto.2004.222">Ohto T, Iwasaki N, Okubo H, Shin K, Matsui A. Life-threatening vocal cord paralysis in a patient with group A xeroderma pigmentosum. <span><span class="ref-journal">Pediatr Neurol. </span>2004;<span class="ref-vol">30</span>:222–4.</span> [<a href="/pubmed/15033209" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15033209</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.opletalova.2014.117">Opletalova K, Bourillon A, Yang W, Pouvelle C, Armier J, Despras E, Ludovic M, Mateus C, Robert C, Kannouche P, Soufir N, Sarasin A. Correlation of phenotype/genotype in a cohort of 23 xeroderma pigmentosum-variant patients reveals 12 new disease-causing POLH mutations. <span><span class="ref-journal">Hum Mutat. </span>2014;<span class="ref-vol">35</span>:117–28.</span> [<a href="/pubmed/24130121" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24130121</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.ramkumar.2011.348">Ramkumar HL, Brooks BP, Cao X, Tamura D, Digiovanna JJ, Kraemer KH, Chan CC. Ophthalmic manifestations and histopathology of xeroderma pigmentosum: two clinicopathological cases and a review of the literature. <span><span class="ref-journal">Surv Ophthalmol. </span>2011;<span class="ref-vol">56</span>:348–61.</span> [<a href="/pmc/articles/PMC3137889/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3137889</span></a>] [<a href="/pubmed/21684361" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21684361</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.rapi_otrin.2003.1507">Rapi&#x00107;-Otrin V, Navazza V, Nardo T, Botta E, McLenigan M, Bisi DC, Levine AS, Stefanini M. True XP group E patients have a defective UV-damaged DNA binding protein complex and mutations in DDB2 which reveal the functional domains of its p48 product. <span><span class="ref-journal">Hum Mol Genet. </span>2003;<span class="ref-vol">12</span>:1507–22.</span> [<a href="/pubmed/12812979" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12812979</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.rapin.2000.1442">Rapin I, Lindenbaum Y, Dickson DW, Kraemer KH, Robbins JH. Cockayne syndrome and xeroderma pigmentosum. <span><span class="ref-journal">Neurology. </span>2000;<span class="ref-vol">55</span>:1442–9.</span> [<a href="/pmc/articles/PMC4459578/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4459578</span></a>] [<a href="/pubmed/11185579" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11185579</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.reichrath.2007.664">Reichrath J. Sunlight, skin cancer and vitamin D: What are the conclusions of recent findings that protection against solar ultraviolet (UV) radiation causes 25-hydroxyvitamin D deficiency in solid organ-transplant recipients, xeroderma pigmentosum, and other risk groups? <span><span class="ref-journal">J Steroid Biochem Mol Biol. </span>2007;<span class="ref-vol">103</span>:664–7.</span> [<a href="/pubmed/17204418" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17204418</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.robbins.1974.221">Robbins JH, Kraemer KH, Lutzner MA, Festoff BW, Coon HG. Xeroderma pigmentosum. An inherited diseases with sun sensitivity, multiple cutaneous neoplasms, and abnormal DNA repair. <span><span class="ref-journal">Ann Intern Med. </span>1974;<span class="ref-vol">80</span>:221–48.</span> [<a href="/pubmed/4811796" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4811796</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.roseeuw.2003.30">Roseeuw D. The treatment of basal skin carcinomas in two sisters with xeroderma pigmentosum. <span><span class="ref-journal">Clin Exp Dermatol. </span>2003;<span class="ref-vol">28</span> Suppl 1:30–2.</span> [<a href="/pubmed/14616810" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14616810</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.ruenger.2012">Ruenger T, DiGiovanna J, Kraemer KH. Hereditary diseases of genome instability and DNA repair. In: Wolff K, Katz S, Goldsmith L, Gilchrist B, Leffell D, Paller A, eds. <em>Fitzpatrick's Dermatology in General Medicine</em>. 8 ed. New York, NY: McGraw-Hill; 2012:1654-71.</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.schubert.2014.22">Schubert S, Lehmann J, Kalfon L, Slor H, Falik-Zaccai TC, Emmert S. Clinical utility gene card for: Xeroderma pigmentosum. <span><span class="ref-journal">Eur J Hum Genet. </span>2014:22.</span> [<a href="/pmc/articles/PMC4060106/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4060106</span></a>] [<a href="/pubmed/24105368" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24105368</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.schwertman.2012.598">Schwertman P, Lagarou A, Dekkers DH, Raams A, van der Hoek AC, Laffeber C, Hoeijmakers JH, Demmers JA, Fousteri M, Vermeulen W, Marteijn JA. UV-sensitive syndrome protein UVSSA recruits USP7 to regulate transcription-coupled repair. <span><span class="ref-journal">Nat Genet. </span>2012;<span class="ref-vol">44</span>:598–602.</span> [<a href="/pubmed/22466611" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22466611</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.sethi.2013.1279">Sethi M, Lehmann AR, Fawcett H, Stefanini M, Jaspers N, Mullard K, Turner S, Robson A, McGibbon D, Sarkany R, Fassihi H. Patients with xeroderma pigmentosum complementation groups C, E and V do not have abnormal sunburn reactions. <span><span class="ref-journal">Br J Dermatol. </span>2013;<span class="ref-vol">169</span>:1279–87.</span> [<a href="/pubmed/23889214" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23889214</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.sidwell.2006.81">Sidwell RU, Sandison A, Wing J, Fawcett HD, Seet JE, Fisher C, Nardo T, Stefanini M, Lehmann AR, Cream JJ. A novel mutation in the XPA gene associated with unusually mild clinical features in a patient who developed a spindle cell melanoma. <span><span class="ref-journal">Br J Dermatol. </span>2006;<span class="ref-vol">155</span>:81–8.</span> [<a href="/pubmed/16792756" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16792756</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.sollitto.1997.942">Sollitto RB, Kraemer KH, DiGiovanna JJ. Normal vitamin D levels can be maintained despite rigorous photoprotection: Six years' experience with xeroderma pigmentosum. <span><span class="ref-journal">J Am Acad Dermatol. </span>1997;<span class="ref-vol">37</span>:942–7.</span> [<a href="/pubmed/9418761" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9418761</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.soufir.2010.1537">Soufir N, Ged C, Bourillon A, Austerlitz F, Chemin C, Stary A, Armier J, Pham D, Khadir K, Roume J, Hadj-Rabia S, Bouadjar B, Taieb A, de Verneuil H, Benchiki H, Grandchamp B, Sarasin A. A prevalent mutation with founder effect in xeroderma pigmentosum group C from north Africa. <span><span class="ref-journal">J Invest Dermatol. </span>2010;<span class="ref-vol">130</span>:1537–42.</span> [<a href="/pubmed/20054342" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20054342</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.stefanini.2008">Stefanini M, Kraemer KHK. Xeroderma pigmentosum. In: Ruggieri M, Pascual-Castroviejo I, Di Rocco C, eds. <em>Neurocutaneous Diseases</em>. New York, NY: Springer; 2008:771-92.</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.sugasawa.2010.29">Sugasawa K. Regulation of damage recognition in mammalian global genomic nucleotide excision repair. <span><span class="ref-journal">Mutat Res. </span>2010;<span class="ref-vol">685</span>:29–37.</span> [<a href="/pubmed/19682467" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19682467</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.takahashi.2010.2481">Takahashi Y, Endo Y, Sugiyama Y, Inoue S, Iijima M, Tomita Y, Kuru S, Takigawa M, Moriwaki S. XPA gene mutations resulting in subtle truncation of protein in xeroderma pigmentosum group A patients with mild skin symptoms. <span><span class="ref-journal">J Invest Dermatol. </span>2010;<span class="ref-vol">130</span>:2481–8.</span> [<a href="/pubmed/20574439" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20574439</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.tamhankar.2015.16">Tamhankar PM, Iyer SV, Ravindran S, Gupta N, Kabra M, Nayak C, Kura M, Sanghavi S, Joshi R, Chennuri VS, Khopkar U. Clinical profile and mutation analysis of xeroderma pigmentosum in Indian patients. <span><span class="ref-journal">Indian J Dermatol Venereol Leprol. </span>2015;<span class="ref-vol">81</span>:16–22.</span> [<a href="/pubmed/25566891" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25566891</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.tamura.2014.146">Tamura D, DiGiovanna JJ, Khan SG, Kraemer KH. Living with xeroderma pigmentosum: comprehensive photoprotection for highly photosensitive patients. <span><span class="ref-journal">Photodermatol Photoimmunol Photomed. </span>2014;<span class="ref-vol">30</span>:146–52.</span> [<a href="/pmc/articles/PMC6334764/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6334764</span></a>] [<a href="/pubmed/24417420" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24417420</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.tamura.2010a.1491">Tamura D, DiGiovanna JJ, Kraemer KH. Founder mutations in xeroderma pigmentosum. <span><span class="ref-journal">J Invest Dermatol. </span>2010a;<span class="ref-vol">130</span>:1491–3.</span> [<a href="/pmc/articles/PMC3486739/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3486739</span></a>] [<a href="/pubmed/20463673" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20463673</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.tamura.b">Tamura D, DiGiovanna JJ, Kraemer KH. Xeroderma pigmentosum. In: Lebwohl MG, Heymann WR, Berth-Jones J, Coulson I, eds. <em>Treatment of Skin Disease: Comprehensive Therapeutic Strategies</em>. 3 ed. London, UK: Elsevier; 2010b:789-92.</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.tamura.2012.1308">Tamura D, Khan SG, Merideth M, DiGiovanna JJ, Tucker MA, Goldstein AM, Oh K-S, Ueda T, Boyle J, Sarihan M, Kraemer KH. Effect of mutations in XPD (ERCC2) on pregnancy and prenatal development in mothers of patients with trichothiodystrophy or xeroderma pigmentosum. <span><span class="ref-journal">Eur J Hum Genet. </span>2012;<span class="ref-vol">20</span>:1308–10.</span> [<a href="/pmc/articles/PMC3499748/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3499748</span></a>] [<a href="/pubmed/22617342" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22617342</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.tamura.2011.1046">Tamura D, Merideth M, DiGiovanna JJ, Zhou X, Tucker MA, Goldstein AM, Brooks BP, Khan SG, Oh KS, Ueda T, Boyle J, Moslehi R, Kraemer KH. High-risk pregnancy and neonatal complications in the DNA repair and transcription disorder trichothiodystrophy: report of 27 affected pregnancies. <span><span class="ref-journal">Prenat Diagn. </span>2011;<span class="ref-vol">31</span>:1046–53.</span> [<a href="/pmc/articles/PMC3266696/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3266696</span></a>] [<a href="/pubmed/21800331" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21800331</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.tanioka.2007.1745">Tanioka M, Masaki T, Ono R, Nagano T, Otoshi-Honda E, Matsumura Y, Takigawa M, Inui H, Miyachi Y, Moriwaki S, Nishigori C. Molecular analysis of DNA polymerase eta gene in Japanese patients diagnosed as xeroderma pigmentosum variant type. <span><span class="ref-journal">J Invest Dermatol. </span>2007;<span class="ref-vol">127</span>:1745–51.</span> [<a href="/pubmed/17344931" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17344931</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.taylor.1997.8658">Taylor EM, Broughton BC, Botta E, Stefanini M, Sarasin A, Jaspers NG, Fawcett H, Harcourt SA, Arlett CF, Lehmann AR. Xeroderma pigmentosum and trichothiodystrophy are associated with different mutations in the XPD (ERCC2) repair/transcription gene. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>1997;<span class="ref-vol">94</span>:8658–63.</span> [<a href="/pmc/articles/PMC23065/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC23065</span></a>] [<a href="/pubmed/9238033" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9238033</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.totonchy.2013.194">Totonchy MB, Tamura D, Pantell MS, Zalewski C, Bradford PT, Merchant SN, Nadol J, Khan SG, Schiffmann R, Pierson TM, Wiggs E, Griffith AJ, Digiovanna JJ, Kraemer KH, Brewer CC. Auditory analysis of xeroderma pigmentosum 1971-2012: hearing function, sun sensitivity and DNA repair predict neurological degeneration. <span><span class="ref-journal">Brain. </span>2013;<span class="ref-vol">136</span>:194–208.</span> [<a href="/pmc/articles/PMC3562077/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3562077</span></a>] [<a href="/pubmed/23365097" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23365097</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.van_steeg.1999.86">van Steeg H, Kraemer KH. Xeroderma pigmentosum and the role of UV-induced DNA damage in skin cancer. <span><span class="ref-journal">Mol Med Today. </span>1999;<span class="ref-vol">5</span>:86–94.</span> [<a href="/pubmed/10200950" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10200950</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.viana.2013.1230">Viana LM, Seyyedi M, Brewer CC, Zalewski C, DiGiovanna JJ, Tamura D, Totonchy M, Kraemer KH, Joseph B, Nadol JB Jr. Histopathology of the inner ear in patients with xeroderma pigmentosum and neurological degeneration. <span><span class="ref-journal">Otol Neurotol. </span>2013;<span class="ref-vol">34</span>:1230–6.</span> [<a href="/pmc/articles/PMC3744623/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3744623</span></a>] [<a href="/pubmed/23928520" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23928520</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.weeda.1997.320">Weeda G, Eveno E, Donker I, Vermeulen W, Chevallier-Lagente O, Taieb A, Stary A, Hoeijmakers JH, Mezzina M, Sarasin A. A mutation in the XPB/ERCC3 DNA repair transcription gene, associated with trichothiodystrophy. <span><span class="ref-journal">Am J Hum Genet. </span>1997;<span class="ref-vol">60</span>:320–9.</span> [<a href="/pmc/articles/PMC1712398/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1712398</span></a>] [<a href="/pubmed/9012405" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9012405</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.wilson.2016.773">Wilson BT, Lochan A, Stark Z, Sutton RE. Novel missense mutations in a conserved loop between ERCC6 (CSB) helicase motifs V and VI: Insights into Cockayne syndrome. <span><span class="ref-journal">Am J Med Genet A. </span>2016;<span class="ref-vol">170</span>:773–6.</span> [<a href="/pubmed/26749132" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26749132</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.yarosh.2001.926">Yarosh D, Klein J, O'Connor A, Hawk J, Rafal E, Wolf P. Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomised study. Xeroderma Pigmentosum Study Group. <span><span class="ref-journal">Lancet. </span>2001;<span class="ref-vol">357</span>:926–9.</span> [<a href="/pubmed/11289350" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11289350</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.zhang.2012.593">Zhang X, Horibata K, Saijo M, Ishigami C, Ukai A, Kanno S, Tahara H, Neilan EG, Honma M, Nohmi T, Yasui A, Tanaka K. Mutations in UVSSA cause UV-sensitive syndrome and destabilize ERCC6 in transcription-coupled DNA repair. <span><span class="ref-journal">Nat Genet. </span>2012;<span class="ref-vol">44</span>:593–7.</span> [<a href="/pubmed/22466612" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22466612</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xp.REF.zhou.2013.831">Zhou X, Khan SG, Tamura D, Ueda T, Boyle J, Compe E, Egly JM, DiGiovanna JJ, Kraemer KH. Abnormal XPD-induced nuclear receptor transactivation in DNA repair disorders: trichothiodystrophy and xeroderma pigmentosum. <span><span class="ref-journal">Eur J Hum Genet. </span>2013;<span class="ref-vol">21</span>:831–7.</span> [<a href="/pmc/articles/PMC3722669/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3722669</span></a>] [<a href="/pubmed/23232694" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23232694</span></a>]</div></li></ul></div></div><div id="xp.Chapter_Notes"><h2 id="_xp_Chapter_Notes_">Chapter Notes</h2><div id="xp.Author_Notes"><h3>Author Notes</h3><p><b>NIH Study 99-C-0099.</b> Examination of Clinical and Laboratory Abnormalities in Patients with Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy is actively recruiting new patients for a study in Bethesda, MD. Click <a href="https://clinicaltrials.gov/ct2/show/NCT00001813" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">here</a> for more information.</p></div><div id="xp.Acknowledgements"><h3>Acknowledgements</h3><p>This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research and National Human Genome Research Institute.</p></div><div id="xp.Author_History"><h3>Author History</h3><p>John J DiGiovanna, MD (2011-present)<br />Kenneth H Kraemer, MD (2003-present)<br />Daniel J Wattendorf, MD; National Institutes of Health (2003-2008)</p></div><div id="xp.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>29 September 2016 (ma) Comprehensive update posted live</div></li><li class="half_rhythm"><div>13 February 2014 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>14 February 2013 (cd) Revision: changes in testing available for <i>POLH</i>, <i>ERCC3</i>, <i>XPA</i>, <i>XPC</i>, and <i>DDB2</i></div></li><li class="half_rhythm"><div>1 November 2012 (cd) Revision: testing for <i>ERCC4</i> mutations available clinically; <a class="figpopup" href="/books/NBK1397/figure/xp.F2/?report=objectonly" target="object" rid-figpopup="figxpF2" rid-ob="figobxpF2">Figure 2</a> added</div></li><li class="half_rhythm"><div>15 March 2012 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> available clinically for <i>ERCC1</i> and <i>ERCC3</i> and no longer available for <i>DDB2</i></div></li><li class="half_rhythm"><div>4 August 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>22 April 2008 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>14 May 2007 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> clinically available for <i>XPA</i> and <i>XPC</i></div></li><li class="half_rhythm"><div>1 June 2006 (cd) Revision: confirmation of <i>XPA</i> and <i>XPC</i> mutations identified in a research lab clinically available</div></li><li class="half_rhythm"><div>15 September 2005 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>24 February 2004 (kk) Revision: Molecular Genetics</div></li><li class="half_rhythm"><div>1 October 2003 (kk) Revision: clinical testing no longer available</div></li><li class="half_rhythm"><div>20 June 2003 (me) Review posted live</div></li><li class="half_rhythm"><div>28 April 2003 (kk) Original submission</div></li></ul><p>Note: Pursuant to 17 USC Section 105 of the United States Copyright Act, the <i>GeneReview</i> "Xeroderma Pigmentosum" is in the public <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> in the United States of America.</p></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1397</span><span class="label">PMID: <a href="/pubmed/20301571" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301571</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/sedt/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/xq28-dup/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1397&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1397/?report=reader">PubReader</a></li><li><a href="/books/NBK1397/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1397" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1397" style="display:none" title="Cite this Page"><div class="bk_tt">Kraemer KH, DiGiovanna JJ. Xeroderma Pigmentosum. 2003 Jun 20 [Updated 2016 Sep 29]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1397/pdf/Bookshelf_NBK1397.pdf">PDF version of this page</a> (921K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#xp.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#xp.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#xp.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#xp.Genetically_Related_Allelic_Disorders" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#xp.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#xp.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#xp.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#xp.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#xp.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#xp.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#xp.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2067[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">ERCC1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=1643[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">DDB2</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=7508[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">XPC</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2071[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">ERCC3</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=7507[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">XPA</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2072[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">ERCC4</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2073[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">ERCC5</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2068[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">ERCC2</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=5429[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">POLH</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1498726" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1498726" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1498726" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1498726" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/18470933" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Persistence of repair proteins at unrepaired DNA damage distinguishes diseases with ERCC2 (XPD) mutations: cancer-prone xeroderma pigmentosum vs. non-cancer-prone trichothiodystrophy.</a><span class="source">[Hum Mutat. 2008]</span><div class="brieflinkpop offscreen_noflow">Persistence of repair proteins at unrepaired DNA damage distinguishes diseases with ERCC2 (XPD) mutations: cancer-prone xeroderma pigmentosum vs. non-cancer-prone trichothiodystrophy.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Boyle J, Ueda T, Oh KS, Imoto K, Tamura D, Jagdeo J, Khan SG, Nadem C, Digiovanna JJ, Kraemer KH. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Hum Mutat. 2008 Oct; 29(10):1194-208. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/22044607" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Xeroderma pigmentosum.</a><span class="source">[Orphanet J Rare Dis. 2011]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Xeroderma pigmentosum.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lehmann AR, McGibbon D, Stefanini M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Orphanet J Rare Dis. 2011 Nov 1; 6:70. Epub 2011 Nov 1.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301575" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fanconi Anemia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fanconi Anemia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Mehta PA, Tolar J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24417420" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Living with xeroderma pigmentosum: comprehensive photoprotection for highly photosensitive patients.</a><span class="source">[Photodermatol Photoimmunol Pho...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Living with xeroderma pigmentosum: comprehensive photoprotection for highly photosensitive patients.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Tamura D, DiGiovanna JJ, Khan SG, Kraemer KH. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Photodermatol Photoimmunol Photomed. 2014 Apr-Jun; 30(2-3):146-52. Epub 2014 Feb 19.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/10699759" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Common pathways for ultraviolet skin carcinogenesis in the repair and replication defective groups of xeroderma pigmentosum.</a><span class="source">[J Dermatol Sci. 2000]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Common pathways for ultraviolet skin carcinogenesis in the repair and replication defective groups of xeroderma pigmentosum.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Cleaver JE. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Dermatol Sci. 2000 May; 23(1):1-11. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301571" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301571" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e0411bbdde0891169a01009">Xeroderma Pigmentosum - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Xeroderma Pigmentosum - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:49:47-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal106&amp;ncbi_phid=CE8D7293E0404AD100000000058701DC&amp;ncbi_session=CE8D7293E0411BA1_1415SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1397%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1397&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1397/&amp;ncbi_pagename=Xeroderma Pigmentosum - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8D7293E0411BA1_1415SID /projects/books/PBooks@5.22 portal106 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>